Kenneth Hess - Publications

Affiliations: 
Rice University, Houston, TX 
Area:
Statistics

500 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Huang ML, Hess K, Ma J, Santiago L, Scoggins ME, Arribas E, Adrada BE, Le-Petross HT, Leung JWT, Yang W, Geiser W, Candelaria RP. Prospective Comparison of Synthesized Mammography with DBT and Full-Field Digital Mammography with DBT Uncovers Recall Disagreements That may Impact Cancer Detection. Academic Radiology. PMID 34538550 DOI: 10.1016/j.acra.2021.08.004  1
2021 Majd NK, Mastall M, Lin H, Dibaj SS, Hess KR, Yuan Y, Garcia MM, Fuller GN, Alfaro KD, Gule-Monroe MK, Huse JT, Khatua S, Rao G, Sandberg DI, Wefel JS, et al. Clinical characterization of adult medulloblastoma and the effect of first-line therapies on outcome; The MD Anderson Cancer Center experience. Neuro-Oncology Advances. 3: vdab079. PMID 34377987 DOI: 10.1093/noajnl/vdab079  1
2021 Olenginski GM, Piacentini J, Harris DR, Runko NA, Papoutsis BM, Alter JR, Hess KR, Brewer SH, Phillips-Piro CM. Structural and spectrophotometric investigation of two unnatural amino-acid altered chromophores in the superfolder green fluorescent protein. Acta Crystallographica. Section D, Structural Biology. 77: 1010-1018. PMID 34342274 DOI: 10.1107/S2059798321006525  1
2021 Cascone T, Sacks RL, Subbiah IM, Drobnitzky N, Piha-Paul SA, Hong DS, Hess KR, Amini B, Bhatt T, Fu S, Naing A, Janku F, Karp D, Falchook GS, Conley AP, et al. Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study. Esmo Open. 6: 100079. PMID 33721621 DOI: 10.1016/j.esmoop.2021.100079  1
2020 Hui D, Mahler DA, Larsson L, Wu J, Thomas S, Harrison CA, Hess K, Lopez-Mattei J, Thompson K, Gomez D, Jeter M, Lin S, Basen-Engquist K, Bruera E. High Flow Nasal Cannula Therapy for Exertional Dyspnea in Cancer Patients: A Pilot Randomized Clinical Trial. The Oncologist. PMID 33289280 DOI: 10.1002/onco.13624  1
2020 Kida K, Hess KR, Lim B, Iwase T, Chainitikun S, Valero V, Lucci A, Le-Petross HC, Woodward WA, Krishnamurthy S, Hortobagyi GN, Tripathy D, Ueno NT. Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer. Cancers. 12. PMID 33114311 DOI: 10.3390/cancers12113105  1
2020 Hegde A, Andreev-Drakhlin AY, Roszik J, Huang L, Liu S, Hess K, Cabanillas M, Hu MI, Busaidy NL, Sherman SI, Dadu R, Grubbs EG, Ali SM, Lee J, Elamin YY, et al. Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. Esmo Open. 5. PMID 33097651 DOI: 10.1136/esmoopen-2020-000799  1
2020 Mendoza T, Sheshadri A, Altan M, Hess K, George G, Stephen B, Castillo L, Rodriguez E, Gong J, Peterson C, Rodon Ahnert J, Fu S, Piha-Paul SA, Pant S, Dumbrava E, et al. Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory. Journal For Immunotherapy of Cancer. 8. PMID 33097611 DOI: 10.1136/jitc-2020-000931  1
2020 Welsh J, Menon H, Chen D, Verma V, Tang C, Altan M, Hess K, de Groot P, Nguyen QN, Varghese R, Comeaux NI, Simon G, Skoulidis F, Chang JY, Papdimitrakopoulou V, et al. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. Journal For Immunotherapy of Cancer. 8. PMID 33051340 DOI: 10.1136/jitc-2020-001001  1
2020 Abdelhafez AH, Musall BC, Adrada BE, Hess K, Son JB, Hwang KP, Candelaria RP, Santiago L, Whitman GJ, Le-Petross HT, Moseley TW, Arribas E, Lane DL, Scoggins ME, Leung JWT, et al. Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC). Breast Cancer Research and Treatment. PMID 32920733 DOI: 10.1007/S10549-020-05917-7  1
2020 Welsh JW, Heymach JV, Guo C, Menon H, Klein K, Cushman TR, Verma V, Hess KR, Shroff G, Tang C, Skoulidis F, Jeter M, Comeaux N, Patel RR, Chen D, et al. Phase I/II Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 32916308 DOI: 10.1016/j.jtho.2020.08.022  1
2020 Atkins JT, George GC, Hess K, Marcelo-Lewis KL, Yuan Y, Borthakur G, Khozin S, LoRusso P, Hong DS. Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials. British Journal of Cancer. PMID 32868897 DOI: 10.1038/S41416-020-01033-X  1
2020 Candelaria RP, Adrada BE, Hess K, Santiago L, Lane DL, Thompson AM, Moulder SL, Huang ML, Arribas EM, Rauch GM, Leung JWT, Symmans WF, Valero V, Ravenberg EE, White JB, et al. Axillary ultrasound during neoadjuvant systemic therapy in triple-negative breast cancer patients. European Journal of Radiology. 130: 109170. PMID 32777736 DOI: 10.1016/J.Ejrad.2020.109170  1
2020 Spak DA, Foxhall L, Rieber A, Hess K, Helvie M, Whitman GJ. Retrospective Review of a Mobile Mammography Screening Program in an Underserved Population within a Large Metropolitan Area. Academic Radiology. PMID 32763059 DOI: 10.1016/J.Acra.2020.07.012  1
2020 Bashour SI, Ibrahim NK, Schomer DF, Hess KR, Gao C, Tripathy D, Fuller GN. Central nervous system miliary metastasis in breast cancer: a case series analysis and proposed identification criteria of a rare metastasis subtype. British Journal of Cancer. PMID 32747747 DOI: 10.1038/s41416-020-1008-2  1
2020 Grant SR, Lei X, Hess KR, Smith GL, Matin SF, Wood CG, Nguyen Q, Frank SJ, Anscher MS, Smith BD, Karam JA, Tang C. Stereotactic Body Radiation Therapy for the Definitive Treatment of Early Stage Kidney Cancer: A Survival Comparison With Surgery, Tumor Ablation, and Observation. Advances in Radiation Oncology. 5: 495-502. PMID 32529146 DOI: 10.1016/J.Adro.2020.01.002  1
2020 Iwase T, Harano K, Masuda H, Kida K, Hess KR, Wang Y, Dirix L, Van Laere SJ, Lucci A, Krishnamurthy S, Woodward WA, Layman RM, Bertucci F, Ueno NT. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC. Bmc Cancer. 20: 430. PMID 32423453 DOI: 10.1186/S12885-020-06940-Z  1
2020 Tapia C, Aung PP, Roy-Chowdhuri S, Xu M, Ouyang F, Alshawa A, Hajjar J, Singh G, Yang V, Castillo L, Le H, Murthy R, Stephen B, Hess KR, Wistuba I, et al. Decrease in tumor content assessed in biopsies is associated with improved treatment outcome response to pembrolizumab in patients with rare tumors. Journal For Immunotherapy of Cancer. 8. PMID 32303619 DOI: 10.1136/jitc-2020-000665  1
2020 Tang C, Lei X, Smith GL, Pan HY, Hess K, Chen A, Hoffman KE, Chapin BF, Kuban DA, Anscher M, Tina Shih YC, Frank SJ, Smith BD. Costs and Complications after a Diagnosis of Prostate Cancer Treated with Time-Efficient Modalities: an Analysis of National Medicare Data. Practical Radiation Oncology. PMID 32298794 DOI: 10.1016/J.Prro.2020.02.014  1
2020 Murthy RK, Song J, Raghavendra AS, Li Y, Hsu L, Hess KR, Barcenas CH, Valero V, Carlson RW, Tripathy D, Hortobagyi GN. Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice. Npj Breast Cancer. 6: 11. PMID 32219153 DOI: 10.1038/s41523-020-0152-4  1
2020 Liu Y, Fan J, Xu T, Ahmadinejad N, Hess K, Lin SH, Zhang J, Liu X, Liu L, Ning B, Liao Z, Hu TY. Extracellular vesicle tetraspanin-8 level predicts distant metastasis in non-small cell lung cancer after concurrent chemoradiation. Science Advances. 6: eaaz6162. PMID 32195353 DOI: 10.1126/Sciadv.Aaz6162  1
2020 Chu YY, Yam C, Chen MK, Chan LC, Xiao M, Wei YK, Yamaguchi H, Lee PC, Han Y, Nie L, Sun X, Moulder SL, Hess KR, Wang B, Hsu JL, et al. Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer. American Journal of Cancer Research. 10: 648-661. PMID 32195033  1
2020 Bagley AF, Anscher MS, Choi S, Frank SJ, Hoffman KE, Kuban DA, McGuire SE, Nguyen QN, Chapin B, Aparicio A, Pezzi TA, Smith GL, Smith BD, Hess K, Tang C. Association of Sociodemographic and Health-Related Factors With Receipt of Nondefinitive Therapy Among Younger Men With High-Risk Prostate Cancer. Jama Network Open. 3: e201255. PMID 32191331 DOI: 10.1001/jamanetworkopen.2020.1255  1
2020 Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, ... ... Hess KR, et al. Phase 2 study of pembrolizumab in patients with advanced rare cancers. Journal For Immunotherapy of Cancer. 8. PMID 32188704 DOI: 10.1136/jitc-2019-000347  1
2020 Yalniz C, Campbell D, Le-Petross C, Shin K, Bevers TB, Hess KR, Whitman GJ. The role of magnetic resonance imaging in patients with palpable breast abnormalities and negative mammographic and sonographic findings. The Breast Journal. PMID 32108973 DOI: 10.1111/Tbj.13793  1
2020 Wang Y, Janku F, Piha-Paul S, Hess K, Broaddus R, Liu L, Shi N, Overman M, Kopetz S, Subbiah V, Naing A, Hong D, Tsimberidou AM, Karp D, Yao J, et al. Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Scientific Reports. 10: 3080. PMID 32080210 DOI: 10.1038/S41598-020-58366-Z  1
2020 Karbasian N, Sohrabi S, Omofoye TS, Le-Petross H, Arun BK, Albarracin CT, Hess KR, Gutierrez-Barrera AM, Whitman GJ. Imaging Features of Triple Negative Breast Cancer and the Effect of BRCA Mutations. Current Problems in Diagnostic Radiology. PMID 32033821 DOI: 10.1067/J.Cpradiol.2020.01.011  1
2020 Mizrahi JD, Rogers JE, Hess KR, Wolff RA, Varadhachary GR, Javle MM, Shroff RT, Ho L, Fogelman DR, Raghav KPS, Overman MJ, Pant S. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Pancreatology : Official Journal of the International Association of Pancreatology (Iap) ... [Et Al.]. PMID 31932214 DOI: 10.1016/j.pan.2020.01.005  1
2020 Yennurajalingam S, Carmack C, Balachandran D, Eng C, Lim B, Delgado M, Guzman DG, Raznahan M, Park M, Hess KR, Williams JL, Lu Z, Ochoa J, Bruera E. Sleep disturbance in patients with cancer: a feasibility study of multimodal therapy. Bmj Supportive & Palliative Care. PMID 31924662 DOI: 10.1136/bmjspcare-2019-001877  1
2020 Adrada BE, Abdelhafez AH, Musall BC, Hess KR, Son JB, Pagel MD, Hwang K, Candelaria RP, Santiago L, Whitman GJ, Le-Petross H, Moseley TW, Arribas E, Lane DL, Scoggins ME, et al. Abstract P6-02-03: Quantitative apparent diffusion coefficient (ADC) radiomics of tumor and peritumoral regions as potential predictors of treatment response to neoadjuvant chemotherapy (NACT) in triple negative breast cancer (TNBC) patients Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P6-02-03  1
2020 Kida K, Hess KR, Lim B, Iwase T, Chainitikun S, Sapon ME, Valero V, Lucci A, Le-Petross C, Woodward WA, Krishnamurthy S, Hortobagyi GN, Tripathy D, Ueno NT. Abstract P5-06-10: Validation of prognostic stage and anatomic stage in the American joint committee on cancer 8th edition for inflammatory breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P5-06-10  1
2020 Abuhadra N, Hess K, Litton J, Rauch G, Thompson A, Lim B, Adrada B, Mittendorf E, Damodaran S, Candelaria R, Arun B, Yang WT, Ueno N, Santiago L, Murthy R, et al. Abstract P1-10-20: Serial TILs: Evaluating the role of mid-treatment tumor infiltrating lymphocytes (TIL) in predicting pathologic complete response (pCR) in early-stage triple negative breast cancer (TNBC) Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P1-10-20  1
2019 Luo M, Eaton CN, Hess KR, Phillips-Piro CM, Brewer SH, Fenlon EE. Paired Spectroscopic and Crystallographic Studies of Proteases. Chemistryselect. 4: 9836-9843. PMID 34169145 DOI: 10.1002/slct.201902049  1
2019 Luo M, Eaton CN, Hess KR, Phillips-Piro CM, Brewer SH, Fenlon EE. Paired Spectroscopic and Crystallographic Studies of Proteases. Chemistryselect. 4: 9836-9843. PMID 34169145 DOI: 10.1002/slct.201902049  1
2019 Dumbrava EEI, Balaji K, Raghav K, Hess K, Javle M, Blum-Murphy M, Ajani J, Kopetz S, Broaddus R, Routbort M, Demirhan M, Zheng X, Pant S, Tsimberidou AM, Subbiah V, et al. Targeting () Amplification Identified by Next-Generation Sequencing in Patients With Advanced or Metastatic Solid Tumors Beyond Conventional Indications. Jco Precision Oncology. 3. PMID 32923865 DOI: 10.1200/PO.18.00345  1
2019 Pairawan S, Hess KR, Janku F, Sánchez NS, Shaw KRM, Eng C, Damodaran S, Javle M, Kaseb AO, Hong DS, Subbiah V, Fu S, Fogelman DR, Raymond VM, Lanman RB, et al. Cell-Free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31852833 DOI: 10.1158/1078-0432.Ccr-19-0306  1
2019 Welsh JW, Tang C, de Groot P, Naing A, Hess KR, Heymach JV, Papadimitrakopoulou VA, Cushman TR, Subbiah V, Chang JY, Simon GR, Ramapriyan R, Barsoumian HB, Menon H, Cortez MA, et al. Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. Cancer Immunology Research. PMID 31658994 DOI: 10.1158/2326-6066.Cir-18-0793  1
2019 Welsh JW, Heymach JV, Chen D, Verma V, Cushman TR, Hess KR, Shroff G, Tang C, Skoulidis F, Jeter M, Menon H, Nguyen QN, Chang JY, Altan M, Papadimitrakopoulou VA, et al. Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31605794 DOI: 10.1016/j.jtho.2019.10.001  1
2019 Habra MA, Stephen B, Campbell M, Hess K, Tapia C, Xu M, Rodon Ahnert J, Jimenez C, Lee JE, Perrier ND, Boraddus RR, Pant S, Subbiah V, Hong DS, Zarifa A, et al. Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma. Journal For Immunotherapy of Cancer. 7: 253. PMID 31533818 DOI: 10.1186/S40425-019-0722-X  1
2019 Chen D, Menon H, Verma V, Seyedin SN, Ajani JA, Hofstetter WL, Nguyen QN, Chang JY, Gomez DR, Amini A, Swisher SG, Blum MA, Younes AI, Barsoumian HB, Erasmus JJ, ... ... Hess KR, et al. Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer. Jama Oncology. PMID 31529018 DOI: 10.1001/jamaoncol.2019.2809  1
2019 Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Barcenas CH, Valero V, Whitman GJ, Schwartz-Gomez J, Mittendorf EA, Thompson AM, Helgason T, et al. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline Pathogenic Variant. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1901304. PMID 31461380 DOI: 10.1200/Jco.19.01304  1
2019 Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, et al. Corrigendum to "Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials" [Lung Cancer 120 (June) (2018) 137-141]. Lung Cancer (Amsterdam, Netherlands). PMID 31445783 DOI: 10.1016/J.Lungcan.2019.08.017  1
2019 Ruiz-Flores L, Whitman GJ, Le-Petross HTC, Hess KR, Parikh JR. Variation in Technical Quality of Breast MRI. Academic Radiology. PMID 31371208 DOI: 10.1016/J.Acra.2019.07.002  1
2019 Martaindale S, Omofoye TS, Teichgraeber DC, Hess KR, Whitman GJ. Imaging Follow-up Versus Surgical Excision for Radial Scars Identified on Tomosynthesis-Guided Core Needle Biopsy. Academic Radiology. PMID 31311772 DOI: 10.1016/J.Acra.2019.05.012  1
2019 Asare EA, Silva-Figueroa A, Hess KR, Busaidy N, Graham PH, Grubbs EG, Lee JE, Williams MD, Perrier ND. Risk of Distant Metastasis in Parathyroid Carcinoma and Its Effect on Survival: A Retrospective Review from a High-Volume Center. Annals of Surgical Oncology. PMID 31111352 DOI: 10.1245/s10434-019-07451-3  1
2019 Eghtedari M, Le-Petross H, Babiera GV, Albarracin CT, Hess KR, Woodtichartpreecha P, Whitman GJ. Not all patients with a diagnosis of a radial scar require excision. The Breast Journal. PMID 31087426 DOI: 10.1111/Tbj.13329  1
2019 Teichgraeber DC, Martaindale S, Omofoye TS, Hess KR, Parikh JR, Whitman GJ. Immediate Migration of Biopsy Clip Markers After Upright Digital Breast Tomosynthesis-Guided Vacuum-Assisted Core Biopsy. Academic Radiology. PMID 31076332 DOI: 10.1016/J.Acra.2019.03.022  1
2019 Baez-Vallecillo L, Raghavendra AS, Hess KR, Barcenas CH, Moulder SL, Tripathy D, Valero V, Murthy RK. Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1). Breast Cancer Research and Treatment. PMID 30977027 DOI: 10.1007/s10549-018-05081-z  1
2019 Hess KR. Beneficial Effect of Adjuvant Dabrafenib Plus Trametinib on Recurrence-Free Survival in Patients With Resected BRAF-Mutant Stage III Melanoma Seems to be Short-Lived. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1801768. PMID 30939097 DOI: 10.1200/JCO.18.01768  0.01
2019 George GC, Iwuanyanwu EC, Buford AS, Piha-Paul SA, Subbiah V, Fu S, Karp DD, Pant S, Hinojosa CO, Hess KR, Cleeland CS, Bernstam EV, Meric-Bernstam F, Hong DS. Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. Journal of Medical Internet Research. 21: e10348. PMID 30869638 DOI: 10.2196/10348  1
2019 Fu C, Gombos DS, Lee J, George GC, Hess K, Whyte A, Hong DS. Erratum: Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions. Oncotarget. 10: 1011-1013. PMID 30847029 DOI: 10.18632/oncotarget.26658  1
2019 Viswanathan A, Vedantam A, Hess KR, Ochoa J, Dougherty PM, Reddy AS, Koyyalagunta D, Reddy S, Bruera E. Minimally Invasive Cordotomy for Refractory Cancer Pain: A Randomized Controlled Trial. The Oncologist. PMID 30796153 DOI: 10.1634/theoncologist.2018-0570  1
2019 Subbiah V, Anderson PM, Kairemo K, Hess KR, Huh WW, Ravi V, Daw NC, Somaiah N, Ludwig JA, Benjamin RS, Chawla SP, Hong DS, Meric-Bernstam F, Ravizzini G, Kleinerman ES, et al. Alpha particle Radium 223 dichloride in high-risk osteosarcoma: a phase I dose escalation trial. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30733229 DOI: 10.1158/1078-0432.Ccr-18-3964  1
2019 Beechar VB, Prabhu SS, Bastos D, Weinberg JS, Stafford RJ, Fuentes D, Hess KR, Rao G. Correction to: Volumetric response of progressing post-SRS lesions treated with laser interstitial thermal therapy. Journal of Neuro-Oncology. PMID 30635762 DOI: 10.1007/S11060-019-03093-3  1
2019 Yam C, Esteva FJ, Patel MM, Raghavendra AS, Ueno NT, Moulder SL, Hess KR, Shroff GS, Hodge S, Koenig KH, Chavez Mac Gregor M, Griner RL, Yeung SJ, Hortobagyi GN, Valero V. Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. Investigational New Drugs. PMID 30610588 DOI: 10.1007/s10637-018-0700-z  1
2019 Helgason T, Damodaran S, Hess KR, Symmans WF, Moulder SL. CLO19-036: Folate Receptor alpha Expression in Metastatic Triple-Negative Breast Cancer (TNBC) Journal of the National Comprehensive Cancer Network. 17: CLO19-036. DOI: 10.6004/JNCCN.2018.7115  0.01
2019 Agosto Salgado S, Waguespack S, Cote G, Hess K, Habra M, Jimenez C, Hu M, Sherman S, Busaidy N, Dadu R, Tatsui C, McCutcheon I, Grubbs E, Williams M, Shah K, et al. MON-554 Brain Metastases in Thyroid Cancer: Molecular Profile and Institutional Experience of a Single Tertiary Referral Center in the Era of Kinase Inhibitor Therapy Journal of the Endocrine Society. 3. DOI: 10.1210/Js.2019-Mon-554  0.01
2019 Mizrahi J, Rogers J, Hess KR, Wolff RA, Varadhachary GR, Shroff RT, Ho L, Fogelman DR, Raghav KPS, Overman MJ, Pant S. FOLFIRINOX in pancreatic cancer patients age 75 years or older. Journal of Clinical Oncology. 37: 362-362. DOI: 10.1200/JCO.2019.37.4_SUPPL.362  0.01
2019 Yennu S, Valero V, Lim B, Booser DJ, Hernandez CD, Lu Z, Liu DD, Busaidy NL, Reuben JM, Williams JL, Hess KR, Basen-Engquist K, Bruera E. High/low dose dexamethasone with physical activity for cancer-related fatigue in patients with advanced cancer: A phase II randomized double blind study. Journal of Clinical Oncology. 37: 110-110. DOI: 10.1200/jco.2019.37.31_suppl.110  0.01
2019 Khan A, Amidi O, Hess KR, Ewer MS, Yusuf W, Banchs J, Palaskas N. Defining cardiotoxicity of doxorubicin and trastuzumab. Journal of Clinical Oncology. 37: e23097-e23097. DOI: 10.1200/JCO.2019.37.15_SUPPL.E23097  0.01
2019 Balema WA, Moseley TW, Weaver O, Hess KR, Brewster AM. The association between volumetric breast density and breast cancer subtypes among women newly diagnosed with breast cancer. Journal of Clinical Oncology. 37: e13115-e13115. DOI: 10.1200/JCO.2019.37.15_SUPPL.E13115  0.01
2019 Hall CS, Hess KR, Ravenberg E, Clayborn A, Meas S, Moulder SL, Thompson AM, Lucci A. Pathologic complete response and serial circulating tumor cell monitoring during neoadjuvant therapy in nonmetastatic triple-negative breast cancer patients. Journal of Clinical Oncology. 37: e12111-e12111. DOI: 10.1200/JCO.2019.37.15_SUPPL.E12111  0.01
2019 Welsh JW, Menon H, Tang C, Verma V, Altan M, Hess KR, de Groot P, Nguyen Q, Simon GR, Skoulidis F, Chang JY, Papadimitrakopoulou V, Heymach J. Randomized phase I/II trial of pembrolizumab with and without radiotherapy for metastatic non-small cell lung cancer. Journal of Clinical Oncology. 37: 9104-9104. DOI: 10.1200/JCO.2019.37.15_SUPPL.9104  0.01
2019 Seth S, Crespo J, Huo L, Thompson AM, Mittendorf EA, Hess KR, Litton JK, Rauch GM, Adrada BE, Damodaran S, Candelaria RP, Arun B, Yang WT, Santiago L, Murthy RK, et al. Evaluation of predictive biomarkers for AR therapy and to identify the LAR subtype of TNBC. Journal of Clinical Oncology. 37: 595-595. DOI: 10.1200/JCO.2019.37.15_SUPPL.595  0.01
2019 Abuhadra N, Hess KR, Litton JK, Rauch GM, Thompson AM, Lim B, Adrada BE, Mittendorf EA, Damodaran S, Candelaria RP, Arun B, Yang WT, Ueno NT, Santiago L, Murthy RK, et al. Beyond TILs: Predictors of pathologic complete response (pCR) in triple-negative breast cancer (TNBC) patients with moderate tumor-infiltrating lymphocytes (TIL) receiving neoadjuvant therapy. Journal of Clinical Oncology. 37: 572-572. DOI: 10.1200/JCO.2019.37.15_SUPPL.572  0.01
2019 Johnson DH, Hailemichael Y, Foo WC, Hess KR, Haymaker CL, Wani KM, Lazar AJ, Saberian CM, Bentebibel SE, Burton EM, Abu-Sbeih H, Wang Y, Hwu P, Diab A. Interleukin-6 is potential target to de-couple checkpoint inhibitor-induced colitis from antitumor immunity. Journal of Clinical Oncology. 37: 2616-2616. DOI: 10.1200/JCO.2019.37.15_SUPPL.2616  0.01
2019 Carmagnani Pestana R, Subbiah IM, Hess KR, Huang L, Liu S, Beltran K, Harrison H, Bryant A, Eshon J, Yap TA, Pant S, Naing A, Hong DS, Meric-Bernstam F, Subbiah V. Re-evaluating eligibility criteria: Analysis of factors leading to nonparticipation and outcomes of patients (pt) with advanced cancer who signed consent but were not treated in early-phase immunotherapy (IO) trials. Journal of Clinical Oncology. 37: 2552-2552. DOI: 10.1200/JCO.2019.37.15_SUPPL.2552  0.01
2019 Hui D, De La Rosa A, Chen J, Delgado-Guay M, Heung Y, Liu DD, Hess KR, Bruera E. Growth of palliative care (PC) in United States cancer centers: A national survey. Journal of Clinical Oncology. 37: 11601-11601. DOI: 10.1200/JCO.2019.37.15_SUPPL.11601  0.01
2019 Hui D, Larsson L, Thomas S, Harrison C, Wu J, Mahler D, Hess KR, Lopez-Mattei J, Thompson K, Gomez DR, Jeter M, Lin SH, Tsao AS, Eapen G, Basen-Engquist K, et al. Effect of high flow oxygen on exertional dyspnea in cancer patients: A double-blind randomized clinical trial. Journal of Clinical Oncology. 37: 11600-11600. DOI: 10.1200/JCO.2019.37.15_SUPPL.11600  0.01
2019 Sen S, Hess KR, Hong DS, Falchook GS, Pestana R, Janku F, Naing A, Benjamin RS, Patel S, Meric-Bernstam F, Subbiah V. Survival and signals of response in advanced sarcoma patients enrolled on phase 1 trials in the era of precision oncology and novel immunotherapies. Journal of Clinical Oncology. 37: 11063-11063. DOI: 10.1200/JCO.2019.37.15_SUPPL.11063  0.01
2019 Sen S, Pestana R, Hess KR, Hong DS, Janku F, Naing A, Falchook GS, Conley AP, Patel S, Meric-Bernstam F, Subbiah V. Precision oncology in sarcoma drug development: Impact of genomic matching on response, clinical benefit, and survival in sarcoma patients on phase 1 trials. Journal of Clinical Oncology. 37: 11018-11018. DOI: 10.1200/JCO.2019.37.15_SUPPL.11018  0.01
2019 Garber H, Raghavendra AS, Hess KR, Arun B, Ibrahim NK. Brain metastasis in patients with hereditary BRCA-mutated invasive breast cancer. Journal of Clinical Oncology. 37: 1074-1074. DOI: 10.1200/JCO.2019.37.15_SUPPL.1074  0.01
2019 Iwase T, Harano K, Masuda H, Kida K, Fernandez JE, Hess K, Wang Y, Woodward W, Layman R, Dirix L, Laere SV, Bertucci F, Ueno N. Abstract P5-05-04: Myc as a poor prognostic marker for ER+ inflammatory breast cancer (IBC): Quantitative estrogen receptor (ER) expression analysis and gene expression analysis in ER+ IBC vs non-IBC Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-P5-05-04  1
2019 Yam C, Raghavendra A, Hess K, Adrada B, Candelaria R, Damodaran S, Gilcrease M, Helgason T, Hortobagyi G, Huo L, Layman R, Lim B, Litton J, Mittendorf E, Murthy R, et al. Abstract P1-15-06: Impact of serial biopsies in triple-negative breast cancer patients receiving neoadjuvant systemic therapy Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-P1-15-06  1
2019 Kurnit KC, Meric-Bernstam F, Hess K, Coleman RL, Bhosale P, Savelieva K, Janku F, Hong D, Naing A, Pant S, Rodon J, Yap TA, Sood AK, Soliman PT, Gershenson DM, et al. Abstract CT020: Phase I dose escalation of olaparib (PARP inhibitor) and selumetinib (MEK Inhibitor) combination in solid tumors with Ras pathway alterations Cancer Research. 79. DOI: 10.1158/1538-7445.Am2019-Ct020  1
2019 Hegde A, Huang L, Liu S, Hess K, Cabanillas M, Hu M, Busaidy N, Sherman S, Simon G, Blumenschein G, Papadimitrakopoulou VA, Hong DS, Meric-Bernstam F, Heymach J, Subbiah V. Abstract 4997: Responsiveness to immune checkpoint inhibitors in RET dependent cancers Cancer Research. 79: 4997-4997. DOI: 10.1158/1538-7445.Am2019-4997  1
2019 Sen S, Pestana RC, Hess K, Hong DS, Subbiah IM, Conley A, Falchook GS, Benjamin RS, Patel S, Meric-Bernstam F, Subbiah V. Abstract 3997: Outcomes of geriatric sarcoma patients enrolled in phase 1 clinical trials Cancer Research. 79: 3997-3997. DOI: 10.1158/1538-7445.Am2019-3997  1
2019 Crespo J, Sahil S, Ravenberg E, Huo L, Hess K, Santiago L, Adrada B, Rauch G, Senthil D, Murthy R, Litton J, Tripathy D, Ueno N, Moulder S, Lim B. Abstract 1409: Characterization of the LAR subtype triple negative breast cancer population Cancer Research. 79: 1409-1409. DOI: 10.1158/1538-7445.Am2019-1409  1
2019 Trevino CR, Murthy RK, Raghavendra AS, Loghin M, Seligman C, Ferguson S, Kamiya-Matsuoka C, Harrison R, Sinicrope KD, Valero V, Tummala S, Hess K, Tripathy D, de Groot J, O’Brien B. LPTO-08. INTRATHECAL TRASTUZUMAB PLUS/MINUS IT TOPOTECAN FOR PATIENTS WITH HER2+ BREAST CANCER AND LEPTOMENINGEAL METASTASIS Neuro-Oncology Advances. 1: i7-i8. DOI: 10.1093/NOAJNL/VDZ014.031  0.01
2019 Majd N, Mastall M, Hess K, Fuller G, Alfaro-Munoz K, Gule-Monroe M, Huse J, Khatua S, Rao G, Sandberg DI, Wefel J, Yeboa D, Zaky W, Mahajan A, Puduvalli V, et al. RARE-47. CHARACTERIZATION OF ADULT MEDULLOBLASTOMA; A RETROSPECTIVE REVIEW OF 200 PATIENTS AT MD ANDERSON CANCER CENTER Neuro-Oncology. 21: vi231-vi232. DOI: 10.1093/Neuonc/Noz175.1191  0.01
2019 Naing A, Meric-Bernstam F, Karp D, Rodon J, Piha-Paul S, Subbiah V, Hong D, Pant S, Fu S, Janku F, Yap T, Tsimberidou A, Dumbrava EEI, Colen R, Hess K, et al. Pembrolizumab in advanced rare cancers Annals of Oncology. 30: v516-v517. DOI: 10.1093/annonc/mdz253.095  0.01
2019 Moulder S, Adrada B, Lim B, Ueno N, Candelaria R, Rauch G, Litton J, Thompson A, Huo L, Hess K. A model using easily evaluated clinical features to identify triple negative breast cancer (TNBC) patients (pts) with high probability of achieving pathologic complete response (pCR) to neoadjuvant systemic therapy (NAST) The Breast. 44: S101-S102. DOI: 10.1016/S0960-9776(19)30349-2  0.01
2019 Grant S, Lei X, Hess K, Smith G, Matin S, Wood C, Karam J, Smith B, Nguyen Q, Frank S, Anscher M, Tang C. Stereotactic Body Radiotherapy for the Definitive Treatment of Early Stage Kidney Cancer: A Survival Comparison with Surgery, Tumor Ablation, and Observation International Journal of Radiation Oncology*Biology*Physics. 105: E254-E255. DOI: 10.1016/J.Ijrobp.2019.06.1952  0.01
2019 Bagley A, Anscher M, Choi S, Frank S, Hoffman K, Kuban D, McGuire S, Nguyen Q, Smith B, Smith G, Chapin B, Aparicio A, Pezzi T, Hess K, Tang C. Factors Affecting Receipt of Non-Definitive Therapy for High-Risk Prostate Cancer: A National Cancer Database Analysis International Journal of Radiation Oncology*Biology*Physics. 105: E452. DOI: 10.1016/J.Ijrobp.2019.06.1498  0.01
2018 Subbiah V, Sen S, Hess KR, Janku F, Hong DS, Khatua S, Karp DD, Munoz J, Falchook GS, Groisberg R, Tsimberidou AM, Sherman SI, Hwu P, Meric-Bernstam F. Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With -Mutated Malignancies. Jco Precision Oncology. 2. PMID 32913986 DOI: 10.1200/PO.18.00189  1
2018 Yam C, Seth S, Hess KR, Mittendorf EA, Murthy RK, Damodaran S, Helgason T, Huo L, Thompson AM, Barton M, Huang ML, Arribas EM, Lane DL, Rauch GM, Adrada BE, et al. Impact of clinical, morphologic and molecular characteristics on response to neoadjuvant systemic therapy (NAST) in metaplastic breast cancer (MpBC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii73-viii74. PMID 32138010 DOI: 10.1093/Annonc/Mdy270.223  1
2018 Kwong LN, De Macedo MP, Haydu L, Joon AY, Tetzlaff MT, Calderone TL, Wu CJ, Kwong MK, Roszik J, Hess KR, Davies MA, Lazar AJ, Gershenwald JE. Biological Validation of RNA Sequencing Data from Formalin-Fixed Paraffin-Embedded Primary Melanomas. Jco Precision Oncology. 2018. PMID 31058252 DOI: 10.1200/PO.17.00259  1
2018 George GC, Buford A, Hess K, Piha-Paul SA, Zinner R, Subbiah V, Hinojosa C, Cleeland CS, Meric-Bernstam F, Bernstam EV, Hong DS. Cancer-Related Internet Use and Online Social Networking Among Patients in an Early-Phase Clinical Trials Clinic at a Comprehensive Cancer Center. Jco Clinical Cancer Informatics. 1-14. PMID 30652565 DOI: 10.1200/CCI.17.00030  1
2018 Janku F, Hess KR, Yap TA. Moving Precision Oncology Forward Amid Myths and Misconceptions. Jama Oncology. PMID 30419079 DOI: 10.1001/jamaoncol.2018.5064  1
2018 Maraka S, Groves MD, Mammoser AG, Melguizo-Gavilanes I, Conrad CA, Tremont-Lukats IW, Loghin ME, O'Brien BJ, Puduvalli VK, Sulman EP, Hess KR, Aldape KD, Gilbert MR, de Groot JF, Alfred Yung WK, et al. Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma. Cancer. PMID 30359477 DOI: 10.1002/Cncr.31811  1
2018 Sen S, Carmagnani Pestana R, Hess K, Viola G, Subbiah V. Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30307530 DOI: 10.1093/annonc/mdy453  1
2018 Wang Y, Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Hess K, Broaddus R, Shan B, Naing A, Hong D, Tsimberidou AM, Karp D, Lu C, Papadimitrakopoulou V, et al. Outcome analysis of Phase I trial patients with metastatic and/or mutant non-small cell lung cancer. Oncotarget. 9: 33258-33270. PMID 30279957 DOI: 10.18632/Oncotarget.25947  1
2018 Dembla V, Somaiah N, Barata P, Hess K, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Shaw K, Meric-Bernstam F, Hong DS. Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. Oncotarget. 9: 33232-33243. PMID 30237864 DOI: 10.18632/Oncotarget.26075  1
2018 Chen X, Low KH, Alexander A, Jiang Y, Karakas C, Hess KR, Carey JP, Bui T, Vijayaraghavan S, Evans KW, Yi M, Ellis DC, Cheung KL, Ellis IO, Fu S, et al. Cyclin E overexpression sensitizes triple negative breast cancer to Wee1 kinase Inhibition. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30181387 DOI: 10.1158/1078-0432.Ccr-18-1446  1
2018 Basho RK, Yam C, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Hong D, Kurzrock R, Hortobagyi GN, et al. Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. The Oncologist. PMID 30139837 DOI: 10.1634/Theoncologist.2017-0498  1
2018 McQuade JL, Daniel CR, Hess KR, Davies MA. Sex as a predictor of response to cancer immunotherapy. The Lancet. Oncology. 19: e376. PMID 30102226 DOI: 10.1016/S1470-2045(18)30483-2  0.01
2018 Ghia AJ, Guha-Thakurta N, Hess K, Yang JN, Settle SH, Sharpe HJ, Li J, McAleer M, Chang EL, Tatsui CE, Brown PD, Rhines LD. Phase 1 study of spinal cord constraint relaxation with single session spine stereotactic radiosurgery in the primary management of patients with inoperable, previously unirradiated metastatic epidural spinal cord compression. International Journal of Radiation Oncology, Biology, Physics. PMID 30099131 DOI: 10.1016/J.Ijrobp.2018.07.2023  1
2018 Murthy RK, Raghavendra AS, Hess KR, Fujii T, Lim B, Barcenas CH, Zhang H, Chavez-Mac-Gregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson AM, Valero V, Moulder SL, Tripathy D, et al. Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience. Clinical Breast Cancer. PMID 30077429 DOI: 10.1016/j.clbc.2018.07.008  1
2018 Speer ME, Adrada BE, Arribas EM, Hess KR, Middleton LP, Whitman GJ. Imaging of Intracystic Papillary Carcinoma. Current Problems in Diagnostic Radiology. PMID 30072190 DOI: 10.1067/J.Cpradiol.2018.05.001  1
2018 Gupta V, Coburn N, Kidane B, Hess KR, Compton C, Ringash J, Darling G, Mahar AL. Survival prediction tools for esophageal and gastroesophageal junction cancer: A systematic review. The Journal of Thoracic and Cardiovascular Surgery. 156: 847-856. PMID 30011772 DOI: 10.1016/j.jtcvs.2018.03.146  1
2018 Vedantam A, Bruera E, Hess KR, Dougherty PM, Viswanathan A. Somatotopy and Organization of Spinothalamic Tracts in the Human Cervical Spinal Cord. Neurosurgery. PMID 30011044 DOI: 10.1093/neuros/nyy330  1
2018 Speer ME, Huang ML, Dogan BE, Adrada BE, Candelaria RP, Hess KR, Hansakul P, Yang WT, Rauch GM. Title: High risk breast lesions identified on MRI-Guided vacuum assisted needlebiopsy: outcome of surgical excision and imaging follow-up. The British Journal of Radiology. 20180300. PMID 29947265 DOI: 10.1259/bjr.20180300  1
2018 Lacourt TE, Vichaya EG, Escalante C, Manzullo EF, Gunn B, Hess KR, Heijnen CJ, Dantzer R. An effort expenditure perspective on cancer-related fatigue. Psychoneuroendocrinology. 96: 109-117. PMID 29929087 DOI: 10.1016/J.Psyneuen.2018.06.009  0.01
2018 Forget MA, Haymaker C, Hess KR, Meng YJ, Creasy C, Karpinets TV, Fulbright OJ, Roszik J, Woodman SE, Kim YU, Sakellariou-Thompson D, Bhatta A, Wahl A, Flores E, Thorsen ST, et al. Prospective analysis of adoptive TIL therapy in patients with metastatic melanoma: response, impact of anti-CTLA4, and biomarkers to predict clinical outcome. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29848573 DOI: 10.1158/1078-0432.Ccr-17-3649  1
2018 Maymani H, Hess K, Groisberg R, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Tsimberidou AM, Pant S, Karp D, Liu S, Sun M, Heymach J, Simon G, et al. Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. Lung Cancer (Amsterdam, Netherlands). 120: 137-141. PMID 29748008 DOI: 10.1016/J.Lungcan.2018.03.020  1
2018 Sen S, Kato S, Agarwal R, Piha-Paul S, Hess K, Karp D, Janku F, Fu S, Naing A, Pant S, Falchook G, Tang C, Wu X, Ye Y, Tsimberidou A, et al. Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. British Journal of Cancer. PMID 29695765 DOI: 10.1038/S41416-018-0068-Z  1
2018 Parseghian CM, Patnana M, Bhosale P, Hess KR, Shih YT, Kim B, Kopetz S, Overman MJ, Varadhachary GR, Javle M, Naing A, Piha-Paul S, Hong D, Le H, Subbiah V, et al. Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. Journal of Immunotherapy (Hagerstown, Md. : 1997). PMID 29668571 DOI: 10.1097/CJI.0000000000000222  1
2018 Weiss A, Bashour SI, Hess K, Thompson AM, Ibrahim NK. Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy. Breast Cancer Research : Bcr. 20: 27. PMID 29661243 DOI: 10.1186/S13058-018-0945-7  1
2018 Uemura MI, French JT, Hess KR, Liu D, Raghav K, Hortobagyi GN, Arun BK, Valero V, Ueno NT, Alvarez RH, Woodward WA, Debeb BG, Moulder SL, Lim B, Tripathy D, et al. Development of CNS metastases and survival in patients with inflammatory breast cancer. Cancer. PMID 29579338 DOI: 10.1002/cncr.31336  1
2018 Hui D, Hess K, Dibaj SS, Arthur J, Dev R, Dalal S, Reddy S, Bruera E. The minimal clinically important difference of the Richmond Agitation-Sedation Scale in patients with cancer with agitated delirium. Cancer. PMID 29469951 DOI: 10.1002/Cncr.31312  1
2018 Sen S, Hess K, Hong DS, Naing A, Piha-Paul S, Janku F, Fu S, Subbiah IM, Liu H, Khanji R, Huang L, Moorthy S, Karp DD, Tsimberidou A, Meric-Bernstam F, et al. Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. British Journal of Cancer. PMID 29462132 DOI: 10.1038/Bjc.2017.480  1
2018 McQuade JL, Daniel CR, Hess KR, Mak C, Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, Lane S, Lee DY, Kaper M, McKean M, Beckermann KE, et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. The Lancet. Oncology. PMID 29449192 DOI: 10.1016/S1470-2045(18)30078-0  1
2018 Kalambo M, Adrada BE, Adeyefa MM, Krishnamurthy S, Hess K, Carkaci S, Whitman GJ. Phyllodes Tumor of the Breast: Ultrasound-Pathology Correlation. Ajr. American Journal of Roentgenology. W1-W7. PMID 29412020 DOI: 10.2214/Ajr.17.18554  1
2018 Levin VA, Ictech SE, Hess KR. Clinical importance of eflornithine (α-difluoromethylornithine) for the treatment of malignant gliomas. Cns Oncology. PMID 29378419 DOI: 10.2217/cns-2017-0031  1
2018 Wei W, Kurita T, Hess KR, Sanft T, Szekely B, Hatzis C, Pusztai L. Comparison of Residual Risk-Based Eligibility vs Tumor Size and Nodal Status for Power Estimates in Adjuvant Trials of Breast Cancer Therapies. Jama Oncology. e175092. PMID 29372234 DOI: 10.1001/jamaoncol.2017.5092  1
2018 Alshawa A, Fujii T, Abu Sbeih H, Blechacz B, Bilen MA, Hess KR, Suarez-Almazor ME, Hong DS, Tsimberidou AM, Gong J, Stephen B, Subbiah V, Piha-Paul SA, Fu S, Mendoza TR, et al. Hepatotoxicity in advanced cancer patients receiving immune-based cancer treatment. Journal of Clinical Oncology. 36: 67-67. DOI: 10.1200/JCO.2018.36.5_SUPPL.67  0.01
2018 Yennu SJ, Carmack CL, Balachandran D, Williams JL, Lu Z, Park M, Hess KR, Ochoa J, Bruera E. Multimodal therapy for the treatment of sleep disturbance in patients with advanced cancer. Journal of Clinical Oncology. 36: 185-185. DOI: 10.1200/JCO.2018.36.34_SUPPL.185  0.01
2018 McQuade JL, Betof Warner A, Li M, Chon J, Haydu LE, Daniel-MacDougall C, Hess KR, Johnson DB, Menzies AM, Davies MA, Shoushtari AN. Association of body mass index (BMI) with overall survival (OS) in metastatic melanoma (MM) patients (pts) treated with combined anti-CTLA4 + anti-PD1. Journal of Clinical Oncology. 36: 9562-9562. DOI: 10.1200/JCO.2018.36.15_SUPPL.9562  0.01
2018 Subbiah V, Cascone T, Hess KR, Subbiah IM, Nelson S, Morikawa N, Nilsson MB, Bhatt T, Ali S, William WN, Raymond VM, Lanman RB, Carbone DP, Salgia R, Owonikoko TK, et al. Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer. Journal of Clinical Oncology. 36: 9035-9035. DOI: 10.1200/Jco.2018.36.15_Suppl.9035  0.01
2018 Yam C, Hess KR, Litton JK, Yang WT, Santiago L, Candelaria RP, Mittendorf EA, Murthy RK, Damodaran S, Helgason T, Huo L, Thompson AM, Barton M, Huang ML, Arribas EM, et al. Impact of metaplastic histology (MpBC) in triple-negative breast cancer (TNBC) patients (pts) receiving neoadjuvant systemic therapy (NAST). Journal of Clinical Oncology. 36: 593-593. DOI: 10.1200/Jco.2018.36.15_Suppl.593  0.01
2018 Basho RK, Trevarton A, Hess KR, Fu C, Lau R, Lin C, Lichtarge O, Yang WT, Symmans WF, Moulder SL. Incidence of PI3K pathway aberrations and their impact on response to neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC) subtypes. Journal of Clinical Oncology. 36: 588-588. DOI: 10.1200/Jco.2018.36.15_Suppl.588  1
2018 Moulder SL, Hess KR, Candelaria RP, Rauch GM, Santiago L, Adrada B, Yang WT, Gilcrease MZ, Huo L, Stauder MC, Arun B, Layman RM, Murthy RK, Damodaran S, Ueno NT, et al. Precision neoadjuvant therapy (P-NAT): A planned interim analysis of a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS). Journal of Clinical Oncology. 36: 518-518. DOI: 10.1200/JCO.2018.36.15_SUPPL.518  0.01
2018 Litton JK, Scoggins M, Hess KR, Adrada B, Barcenas CH, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Thompson AM, Whitman GJ, Ibrahim NK, Moulder SL, Schwartz-Gomez J, Mittendorf EA, et al. Neoadjuvant talazoparib (TALA) for operable breast cancer patients with a BRCA mutation (BRCA Journal of Clinical Oncology. 36: 508-508. DOI: 10.1200/Jco.2018.36.15_Suppl.508  1
2018 Sen S, Hess KR, Hong DS, Naing A, Huang L, Meric-Bernstam F, Subbiah V. Impact of immune checkpoint inhibitor dose on toxicity, response rate, and survival: A pooled analysis of dose escalation phase 1 trials. Journal of Clinical Oncology. 36: 3077-3077. DOI: 10.1200/JCO.2018.36.15_SUPPL.3077  0.01
2018 Groisberg R, Hess KR, Hong DS, Heymach J, Naing A, Piha-Paul SA, Janku F, Javle MM, Hu MI, Conley AP, Meric-Bernstam F, Subbiah V. Outcomes of patients with gene fusion driven cancers treated on early phase clinical trials. Journal of Clinical Oncology. 36: 2590-2590. DOI: 10.1200/JCO.2018.36.15_SUPPL.2590  0.01
2018 Sen S, Hess KR, Roszik J, Shaw KR, Heymach J, Huang L, Schwartz GK, Meric-Bernstam F, Subbiah V. Characterization of KEAP1-NRF2 genomic alterations across diverse tumor types: Co-occurring alterations, survival outcomes, and implications for targeting cancer metabolism. Journal of Clinical Oncology. 36: 2558-2558. DOI: 10.1200/JCO.2018.36.15_SUPPL.2558  0.01
2018 Maraka S, Groves MD, Mammoser AG, Melguizo-Gavilanes I, Conrad CA, Tremont-Lukats I, Loghin ME, O'Brien BJ, Puduvalli VK, Sulman EP, Hess KR, Aldape KD, Gilbert MR, De Groot JF, Yung WKA, et al. Phase I factorial study of temozolomide plus memantine, mefloquine, and metformin as post-radiation adjuvant therapy for newly diagnosed glioblastoma. Journal of Clinical Oncology. 36: 2044-2044. DOI: 10.1200/Jco.2018.36.15_Suppl.2044  0.01
2018 Kheder E, Xing Y, Hess KR, Janku F, Shaw KR, Huang L, Patel K, Meric-Bernstam F, Subbiah V. Non-V600 BRAF mutations in advanced malignancies: Prevalence and survival impact. Journal of Clinical Oncology. 36: 12100-12100. DOI: 10.1200/JCO.2018.36.15_SUPPL.12100  0.01
2018 Kheder E, Hess KR, Xing Y, Cortez MA, Subbiah V, Janku F, Fu S, Naing A, Karp DD, Piha-Paul SA, Yap TA, Pant S, Rodon Ahnert J, Tawbi HA, Welsh JW, et al. TP53 mutations and programmed cell death ligand-1 expression in solid tumors: Associations with clinical factors and outcomes. Journal of Clinical Oncology. 36: 12052-12052. DOI: 10.1200/JCO.2018.36.15_SUPPL.12052  0.01
2018 Pairawan SS, Hess KR, Janku F, Sanchez NS, Eng C, Damodaran S, Javle MM, Kaseb AO, Hong DS, Subbiah V, Fu S, Fogelman DR, Raymond VM, Lanman RB, Meric-Bernstam F. Cell-free circulating tumor DNA somatic alteration burden and its impact on survival in metastatic cancer. Journal of Clinical Oncology. 36: 12022-12022. DOI: 10.1200/Jco.2018.36.15_Suppl.12022  1
2018 Yam C, Santiago L, Candelaria R, Adrada B, Rauch G, Hess K, Litton J, Piwnica-Worms H, Mittendorf E, Ueno N, Lim B, Murthy R, Damodaran S, Helgason T, Huo L, et al. Abstract P6-03-05: Risk of needle-track seeding with serial ultrasound guided biopsies in triple negative breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P6-03-05  1
2018 Yam C, Huo L, Hess K, Litton J, Yang W, Piwnica-Worms H, Mittendorf E, Ueno N, Lim B, Murthy R, Damodaran S, Helgason T, Thompson A, Santiago L, Candelaria R, et al. Abstract P1-07-22: Androgen receptor positivity is associated with nodal disease in triple negative breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P1-07-22  1
2018 Sen S, Hong DS, Hess K, Meric-Bernstam F, Subbiah V. Abstract A199: Association of immune checkpoint inhibitor dose and survival in phase I clinical trials: is it time to redefine the recommended phase II dose Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A199  1
2018 Piha-Paul SA, Xiong WW, Moss T, Mostorino RM, Sedelmeier S, Hess K, Fu S, Hong D, Janku F, Karp D, Naing A, Pant S, Rodon J, Subbiah V, Tsimberidou AM, et al. Abstract A096: Phase II study of the PARP inhibitor talazoparib in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, aberrations in other BRCA pathway genes, and germline mutations in BRCA1/2 (not breast or ovarian cancer) Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-A096  1
2018 Gupta V, Coburn N, Kidane B, Hess K, Compton C, Ringash J, Darling G, Mahar A. PS01.182: TOOLS FOR INDIVIDUALIZED SURVIVAL PREDICTION IN ESOPHAGEAL AND GASTROESOPHAGEAL JUNCTION CANCER Diseases of the Esophagus. 31: 101-101. DOI: 10.1093/DOTE/DOY089.PS01.182  0.01
2018 Hall C, Hess K, Ravenberg L, Clayborn A, Rauch G, Candelaria R, Mittendorf E, Moulder S, Thompson A, Lucci A. Prognostic implications of circulating tumor cells (CTCs) after neoadjuvant chemotherapy for triple negative breast cancer (TNBC) Annals of Oncology. 29: viii72. DOI: 10.1093/ANNONC/MDY270.220  0.01
2018 Litton J, Moulder S, Hess K, Damodaran S, Rauch G, Candelaria R, Adrada B, Symmans F, Murthy R, Helgason T, Clayborn A, Prabhakaran S, Valero V, Thompson A, Mittendorf E. Neoadjuvant trial of nab-paclitaxel and atezolizumab (Atezo), a PD-L1 inhibitor, in patients (pts) with chemo-insensitive triple negative breast cancer (TNBC) Annals of Oncology. 29: viii72. DOI: 10.1093/ANNONC/MDY270.219  0.01
2018 Welsh J, Heymach J, Cushman T, Hess K, Shroff G, Tang C, Skoulidis F, Jeter M, Nguyen Q, Chang J, Papadimitrakopoulou V, Gomez D, Sharma P, Allison J, Raju U, et al. Phase I Trial of MK-3475 and Concurrent Chemoradiotherapy for Limited-Stage Small Cell Lung Cancer International Journal of Radiation Oncology*Biology*Physics. 102: e727. DOI: 10.1016/J.Ijrobp.2018.07.1950  0.01
2018 Welsh J, Heymach J, Cadena A, Cushman T, Hess K, Shroff G, Tang C, Skoulidis F, Jeter M, Nguyen Q, Chang J, Papadimitrakopoulou V, Gomez D, Sharma P, Allison J, et al. Phase I Trial of MK-3475 and Concurrent Radiation for the Elimination of Extensive-Stage Small Cell Lung Cancer International Journal of Radiation Oncology*Biology*Physics. 102: S18. DOI: 10.1016/J.Ijrobp.2018.06.133  0.01
2017 Parseghian C, Patnana M, Bhosale P, Hess K, Kopetz S, Overman M, Naing A, Piha-Paul S, Subbiah V, Hong D, Le H, Pant S. Evaluating for pseudoprogression in colorectal and pancreatic tumors treated with immunotherapy. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 28: iii9. PMID 32136058 DOI: 10.1093/annonc/mdx263.022  1
2017 Jensen G, Tang C, Hess KR, Bishop AJ, Pan HY, Li J, Yang JN, Tannir NM, Amini B, Tatsui C, Rhines L, Brown PD, Ghia AJ. Internal validation of the prognostic index for spine metastasis (PRISM) for stratifying survival in patients treated with spinal stereotactic radiosurgery. Journal of Radiosurgery and Sbrt. 5: 25-34. PMID 29296460  1
2017 Groisberg R, Hong DS, Behrang A, Hess K, Janku F, Piha-Paul S, Naing A, Fu S, Benjamin R, Patel S, Somaiah N, Conley A, Meric-Bernstam F, Subbiah V. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. Journal For Immunotherapy of Cancer. 5: 100. PMID 29254498 DOI: 10.1186/S40425-017-0301-Y  1
2017 Litton JK, Scoggins M, Ramirez DL, Murthy RK, Whitman GJ, Hess KR, Adrada BE, Moulder SL, Barcenas CH, Valero V, Gomez JS, Mittendorf EA, Thompson A, Helgason T, Mills GB, et al. A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline BRCA mutation demonstrates marked activity. Npj Breast Cancer. 3: 49. PMID 29238749 DOI: 10.1038/s41523-017-0052-4  1
2017 Beechar VB, Prabhu SS, Bastos D, Weinberg JS, Stafford RJ, Fuentes D, Hess KR, Rao G. Volumetric response of progressing post-SRS lesions treated with laser interstitial thermal therapy. Journal of Neuro-Oncology. PMID 29204838 DOI: 10.1007/S11060-017-2694-3  1
2017 Boonyawan K, Hess KR, Yang J, Long L, Wang Q, Ezhilarasan R, Auia A, Alfaro-Munoz KD, de Groot JF, Bhat KP, Sulman EP. A relative increase in circulating platelets following chemoradiation predicts for poor survival of patients with glioblastoma. Oncotarget. 8: 90488-90495. PMID 29163847 DOI: 10.18632/Oncotarget.21799  1
2017 Dembla V, Groisberg R, Hess K, Fu S, Wheler J, Hong DS, Janku F, Zinner R, Piha-Paul SA, Ravi V, Benjamin RS, Patel S, Somaiah N, Herzog CE, Karp DD, et al. Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. Scientific Reports. 7: 15963. PMID 29162825 DOI: 10.1038/s41598-017-13114-8  1
2017 Iyer P, Dadu R, Ferrarotto R, Busaidy N, Habra MA, Zafereo M, Gross ND, Hess K, Gule-Monroe M, Williams MD, Cabanillas M. Real world experience with targeted therapy for the treatment of anaplastic thyroid carcinoma. Thyroid : Official Journal of the American Thyroid Association. PMID 29161986 DOI: 10.1089/thy.2017.0285  1
2017 Fujii T, Colen RR, Bilen MA, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Tsimberidou A, Janku F, Gong J, Stephen B, Subbiah V, Piha-Paul SA, Fu S, et al. Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Investigational New Drugs. PMID 29159766 DOI: 10.1007/s10637-017-0534-0  1
2017 Goldstein JB, Tang C, Hess KR, Hong D, Subbiah V, Janku F, Fu S, Karp DD, Naing A, Tsimberidou AM, Wheler J, Zinner R, Javle M, Varadhachary GR, Wolff RA, et al. Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. Oncotarget. 8: 87163-87173. PMID 29152071 DOI: 10.18632/oncotarget.19897  1
2017 Sen S, Meric-Bernstam F, Hong DS, Hess KR, Subbiah V. Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma Tumors. Journal of the National Cancer Institute. 109. PMID 29117359 DOI: 10.1093/jnci/djx094  1
2017 Tsimberidou AM, Hong DS, Ye Y, Cartwright C, Wheler JJ, Falchook GS, Naing A, Fu S, Piha-Paul S, Janku F, Meric-Bernstam F, Hwu P, Kee B, Kies MS, Broaddus R, ... ... Hess KR, et al. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine Study. Jco Precision Oncology. 2017. PMID 29082359 DOI: 10.1200/PO.17.00002  1
2017 Colen RR, Fujii T, Bilen MA, Kotrotsou A, Abrol S, Hess KR, Hajjar J, Suarez-Almazor ME, Alshawa A, Hong DS, Giniebra-Camejo D, Stephen B, Subbiah V, Sheshadri A, Mendoza T, et al. Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. Investigational New Drugs. PMID 29075985 DOI: 10.1007/S10637-017-0524-2  1
2017 Pezzi TA, Tang C, Swanick CW, Fang P, Hess K, Xu T, Hahn SM, Chang JY, Liao Z, Gomez D. Patterns and correlates of treatment failure in relation to isodose distribution in non-small cell lung cancer: An analysis of 1522 patients in the modern era. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 29054376 DOI: 10.1016/J.Radonc.2017.09.018  1
2017 Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, Lazar AJ, Faries MB, Kirkwood JM, McArthur GA, Haydu LE, Eggermont AMM, Flaherty KT, Balch CM, Thompson JF, et al. Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. Ca: a Cancer Journal For Clinicians. PMID 29028110 DOI: 10.3322/caac.21409  1
2017 Hui D, Frisbee-Hume S, Wilson A, Dibaj SS, Nguyen T, De La Cruz M, Walker P, Zhukovsky DS, Delgado-Guay M, Vidal M, Epner D, Reddy A, Tanco K, Williams J, Hall S, ... ... Hess K, et al. Effect of Lorazepam With Haloperidol vs Haloperidol Alone on Agitated Delirium in Patients With Advanced Cancer Receiving Palliative Care: A Randomized Clinical Trial. Jama. 318: 1047-1056. PMID 28975307 DOI: 10.1001/Jama.2017.11468  1
2017 Fu C, Gombos DS, Lee J, George GC, Hess K, Whyte A, Hong DS. Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions. Oncotarget. 8: 58709-58727. PMID 28938590 DOI: 10.18632/Oncotarget.17634  1
2017 An Y, Jiang W, Kim BYS, Qian JM, Tang C, Fang P, Logan J, D'Souza NM, Haydu LE, Wang XA, Hess KR, Kluger H, Glitza IC, Mahajan A, Welsh JW, et al. Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTL-4 treatment is associated with improved intracranial control. Radiotherapy and Oncology : Journal of the European Society For Therapeutic Radiology and Oncology. PMID 28916225 DOI: 10.1016/J.Radonc.2017.08.009  1
2017 Yennurajalingam S, Tannir NM, Williams JL, Lu Z, Hess KR, Frisbee-Hume S, House HL, Lim ZD, Lim KH, Lopez G, Reddy A, Azhar A, Wong A, Patel SM, Kuban DA, et al. A Double-Blind, Randomized, Placebo-Controlled Trial of Panax Ginseng for Cancer-Related Fatigue in Patients With Advanced Cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 15: 1111-1120. PMID 28874596 DOI: 10.6004/jnccn.2017.0149  1
2017 Mahar AL, Compton C, Halabi S, Hess KR, Weiser MR, Groome PA. Personalizing prognosis in colorectal cancer: A systematic review of the quality and nature of clinical prognostic tools for survival outcomes. Journal of Surgical Oncology. PMID 28767139 DOI: 10.1002/jso.24774  1
2017 Hossain MB, Shifat R, Li J, Luo X, Hess KR, Rivera-Molina Y, Martinez FP, Jiang H, Lang FF, Hung MC, Fueyo J, Gomez-Manzano C. TIE2 associates with caveolae and regulates caveolin-1 to promote their nuclear translocation. Molecular and Cellular Biology. PMID 28760776 DOI: 10.1128/Mcb.00142-17  1
2017 Jensen GL, Tang C, Hess KR, Liao Z, Gomez DR. Patterns of metastatic progression after definitive radiation therapy for early-stage and locally advanced non-small cell lung cancer. Clinical & Experimental Metastasis. PMID 28744603 DOI: 10.1007/s10585-017-9850-1  1
2017 Bilen MA, Hess KR, Subudhi SK, Aparicio A, Kim J, Zurita-Saavedra AJ, Araujo JC, Corn PG, Stover J, Lin SH, Logothetis CJ, Tu SM. Clinical predictors of survival in patients with castration-resistant prostate cancer receiving sipuleucel-T cellular immunotherapy. Cancer Chemotherapy and Pharmacology. PMID 28730293 DOI: 10.1007/S00280-017-3391-9  1
2017 Kehl KL, Fullmer CP, Fu S, George GC, Hess KR, Janku F, Karp DD, Kato S, Kizer CK, Kurzrock R, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, et al. Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28729355 DOI: 10.1158/1078-0432.Ccr-16-3027  1
2017 Mahajan A, Ahmed S, McAleer MF, Weinberg JS, Li J, Brown P, Settle S, Prabhu SS, Lang FF, Levine N, McGovern S, Sulman E, McCutcheon IE, Azeem S, Cahill D, ... ... Hess KR, et al. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. The Lancet. Oncology. PMID 28687375 DOI: 10.1016/S1470-2045(17)30414-X  1
2017 Fu C, Gombos DS, Lee J, George GC, Hess K, Whyte A, Hong DS. Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions. Oncotarget. PMID 28549348 DOI: 10.18632/oncotarget.17634  1
2017 Shahar T, Rozovski U, Hess KR, Hossain A, Gumin J, Gao F, Fuller GN, Goodman L, Sulman EP, Lang FF. Percentage of mesenchymal stem cells in high-grade glioma tumor samples correlates with patient survival. Neuro-Oncology. 19: 660-668. PMID 28453745 DOI: 10.1093/Neuonc/Now239  1
2017 Wang Z, Piha-Paul S, Janku F, Subbiah V, Shi N, Gong J, Wathoo C, Shaw K, Hess K, Broaddus R, Naing A, Hong D, Tsimberidou AM, Karp D, Yao J, et al. Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. Oncotarget. PMID 28430579 DOI: 10.18632/Oncotarget.16840  1
2017 Silva-Figueroa AM, Hess KR, Williams MD, Clarke CN, Christakis I, Graham PH, Grubbs EG, Lee JE, Busaidy NL, Perrier ND. Prognostic Scoring System to Risk Stratify Parathyroid Carcinoma. Journal of the American College of Surgeons. PMID 28427885 DOI: 10.1016/j.jamcollsurg.2017.01.060  1
2017 Keskin SK, Msaouel P, Hess KR, Yu KJ, Matin SF, Sircar K, Tamboli P, Jonasch E, Wood CG, Karam JA, Tannir NM. Outcomes of Patients with Renal Cell Carcinoma and Sarcomatoid Dedifferentiation Treated with Nephrectomy and Systemic Therapies Over Three Decades: Comparison Between the Cytokine (1987-2005) and the Targeted Therapy (2006-2015) Eras. The Journal of Urology. PMID 28411072 DOI: 10.1016/j.juro.2017.04.067  1
2017 Le-Petross HT, Hess KR, Knudtson JD, Lane DL, Moseley TW, Geiser WR, Whitman GJ. Effect of Mammography on Marker Clip Migration After Stereotactic-Guided Core Needle Breast Biopsy. Current Problems in Diagnostic Radiology. PMID 28390794 DOI: 10.1067/J.Cpradiol.2017.02.001  1
2017 Bugano DD, Hess KR, Jardim DL, Zer A, Meric-Bernstam F, Siu LL, Razak AR, Hong DS. Use of expansion cohorts in phase 1 trials and probability of success in phase 2 for 381 anticancer drugs. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28377482 DOI: 10.1158/1078-0432.CCR-16-2354  1
2017 Hu X, Martinez-Ledesma E, Zheng S, Kim H, Barthel F, Jiang T, Hess KR, Verhaak RG. Multigene signature for predicting prognosis of patients with 1p19q co-deletion diffuse glioma. Neuro-Oncology. PMID 28340142 DOI: 10.1093/neuonc/now285  0.01
2017 Vedantam A, Hou P, Chi TL, Hess KR, Dougherty PM, Bruera E, Viswanathan A. Postoperative MRI Evaluation of a Radiofrequency Cordotomy Lesion for Intractable Cancer Pain. Ajnr. American Journal of Neuroradiology. PMID 28209581 DOI: 10.3174/ajnr.A5100  1
2017 Huang ML, Speer M, Dogan BE, Rauch GM, Candelaria RP, Adrada BE, Hess KR, Yang WT. Imaging-Concordant Benign MRI-Guided Vacuum-Assisted Breast Biopsy May Not Warrant MRI Follow-Up. Ajr. American Journal of Roentgenology. 1-7. PMID 28140609 DOI: 10.2214/AJR.16.16576  1
2017 Vedantam A, Hou P, Chi TL, Dougherty PM, Hess KR, Viswanathan A. Use of Spinal Cord Diffusion Tensor Imaging to Quantify Neural Ablation and Evaluate Outcome after Percutaneous Cordotomy for Intractable Cancer Pain. Stereotactic and Functional Neurosurgery. 95: 34-39. PMID 28088799 DOI: 10.1159/000453279  1
2017 Rao SN, Zafereo M, Dadu R, Busaidy N, Hess K, Cote GJ, Williams MD, William WN, Sandulache VC, Gross ND, Gunn B, Lu C, Ferrarotto R, Lai SY, Cabanillas M. Patterns of Treatment Failure in Anaplastic Thyroid Carcinoma. Thyroid : Official Journal of the American Thyroid Association. PMID 28068873 DOI: 10.1089/Thy.2016.0395  1
2017 Forget M, Haymaker CL, Hess KR, Roszik J, Woodman SE, Fulbright OJ, Wahl A, Flores E, Thorsen ST, Tavera RJ, Ramachandran R, Amaria RN, Hwu P, Bernatchez C. The impact of checkpoint blockade prior to adoptive cell therapy using tumor-infiltrating lymphocytes for metastatic melanoma: An update from MD Anderson Cancer Center. Journal of Clinical Oncology. 35: 138-138. DOI: 10.1200/JCO.2017.35.7_SUPPL.138  0.01
2017 Keskin SK, Msaouel P, Hess KR, Matin SF, Jonasch E, Wood CG, Karam JA, Tannir NM. Outcomes of patients (pts) with renal cell carcinoma and sarcomatoid dedifferentiation (sRCC) treated with nephrectomy (Nx) and systemic therapies (T) over three decades: The MD Anderson Cancer Center (MDACC) experience. Journal of Clinical Oncology. 35: 534-534. DOI: 10.1200/JCO.2017.35.6_SUPPL.534  0.01
2017 Subbiah IM, Hess KR, Fujii T, Lui A, Subbiah V, Naing A, Hong DS. Integration of supportive care in immuno-oncology trials: Investigating the incidence and severity of immune-related toxicities among older adults versus mid-age patients on immunotherapy-based phase I clinical trials. Journal of Clinical Oncology. 35: 152-152. DOI: 10.1200/JCO.2017.35.31_SUPPL.152  0.01
2017 Yam C, Hess KR, Litton JK, Yang WT, Piwnica-Worms H, Mittendorf EA, Ueno NT, Lim B, Murthy RK, Damodaran SK, Helgason T, Huo L, Thompson AM, Gilcrease M, Santiago L, et al. A randomized, triple negative breast cancer enrolling trial to confirm molecular profiling improves survival (ARTEMIS). Journal of Clinical Oncology. 35: TPS590-TPS590. DOI: 10.1200/Jco.2017.35.15_Suppl.Tps590  0.01
2017 Varadhachary GR, Raghav KPS, Pant S, Janku F, Fu S, Hong DS, Piha-Paul SA, Colen RR, Subbiah V, Painter J, Tsimberidou AM, Stephen B, Karp DD, McQuinn L, Mendoza TR, ... Hess KR, et al. Phase II study for the evaluation of efficacy of pembrolizumab (MK-3475) in patients with cancer of unknown primary. Journal of Clinical Oncology. 35: TPS3103-TPS3103. DOI: 10.1200/JCO.2017.35.15_SUPPL.TPS3103  0.01
2017 Naing A, Fu S, Tsimberidou AM, Pant S, Piha-Paul SA, Janku F, Hong DS, Colen RR, Carter BW, Evans E, Tawbi HA, Karp DD, Subbiah V, Dev R, Hess KR, et al. Phase IB study to evaluate the safety of selinexor in combination with multiple standard chemotherapy agents in patients with advanced malignancies. Journal of Clinical Oncology. 35: TPS2603-TPS2603. DOI: 10.1200/JCO.2017.35.15_SUPPL.TPS2603  0.01
2017 Fellman BM, Hess KR. Phase I clinical trials in oncology: A review of the old and a look at the new. Journal of Clinical Oncology. 35: e14030-e14030. DOI: 10.1200/JCO.2017.35.15_SUPPL.E14030  0.01
2017 Boonyawan K, Yang J, Long L, Wang Q, Ezhilarasan R, Alessandra A, Hess KR, Alfaro K, Groot JFD, Bhat K, Sulman EP. Relative thrombocytosis following chemoradiation of patients with glioblastoma to predict survival. Journal of Clinical Oncology. 35. DOI: 10.1200/Jco.2017.35.15_Suppl.E13527  1
2017 Murthy RK, Fujii T, Hess KR, Raghavendra AS, Lim B, Barcenas CH, Zhang HA, Chavez-Mac Gregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson AM, Valero V, Tripathy D, Ueno NT. Effect of neoadjuvant pertuzumab-containing regimens on pathologic complete response rates in stage II-III HER2-neu positive breast cancer: A retrospective, single institutional experience. Journal of Clinical Oncology. 35: 580-580. DOI: 10.1200/JCO.2017.35.15_SUPPL.580  0.01
2017 Weiss A, Bashour S, Hsu L, Hess KR, Thompson AM, Ibrahim NK. Effect of neoadjuvant chemotherapy regimen choice in patients with breast cancer with pathologic complete response. Journal of Clinical Oncology. 35: 570-570. DOI: 10.1200/JCO.2017.35.15_SUPPL.570  0.01
2017 Yennu S, Basen-Engquist K, Reed VK, Carmack CL, Lee A, Mahmood U, Choi S, Hess KR, Wu J, Williams JL, Lu Z, Cella D, Kuban DA, Bruera E. Multimodal therapy for cancer related fatigue in patients with prostate cancer receiving radiotherapy and androgen deprivation therapy. Journal of Clinical Oncology. 35: 10114-10114. DOI: 10.1200/JCO.2017.35.15_SUPPL.10114  0.01
2017 Subbiah IM, Hess KR, Fujii T, Alshawa A, Lui A, Roy S, Khanji R, Subbiah V, Naing A, Hong DS. Immuno-oncology and the elderly: A comparative analysis of participation and toxicities of senior adults aged 65 years and above vs mid age and adolescent/young adult patients on immunotherapy-based phase I clinical trials. Journal of Clinical Oncology. 35: 10034-10034. DOI: 10.1200/JCO.2017.35.15_SUPPL.10034  0.01
2017 Hui D, Frisbee-Hume S, Wilson A, Dibaj S, Nguyen T, De La Cruz MGJ, Walker P, Delgado-Guay M, Vidal M, Zhukovsky DS, Epner DE, Reddy AS, Tanco K, Williams JL, Hall S, ... ... Hess KR, et al. Lorazepam as an adjuvant to haloperidol for agitated delirium at the end of life: A double-blind randomized controlled trial. Journal of Clinical Oncology. 35: 10003-10003. DOI: 10.1200/JCO.2017.35.15_SUPPL.10003  0.01
2017 Báez-Vallecillo L, Raghavendra AS, Hess K, Moulder S, Tripathy D, Valero V, Murthy R. Abstract P4-21-20: Lapatinib after pertuzumab and ado-trastuzumab emtansine in metastatic HER2-positive breast cancer Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P4-21-20  1
2017 Moulder S, Hess K, Rauch M, Astrada B, Litton J, Mittendorf E, Ueno N, Tripathy D, Lim B, Piwnica-Worms H, Thompson A, Symmans W. Abstract OT2-01-22: NCT02456857: A phase II trial of liposomal doxorubicin, bevacizumab and everolimus (DAE) in patients (pts) with localized triple-negative breast cancer (TNBC) with tumors predicted insensitive to standard neoadjuvant chemotherapy (NACT) Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-Ot2-01-22  1
2017 Lim B, Helgason T, Hess K, Piwnica-Worms H, Yang W, Adrada B, Rauch G, Gilcrease M, Symmans F, Huo L, Mittendorf E, Thompson A, Stacy M, Debu T, Ueno N. Abstract OT2-01-20: Phase IIB study of neoadjuvant panitumumab combined with carboplatin and paclitaxel (PaCT) for anthracycline-resistant triple-negative breast cancer (TNBC) Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-Ot2-01-20  1
2017 Litton J, Moulder S, Helgason T, Clayborn A, Rauch G, Gilcrease M, Adrada B, Huo L, Hess K, Symmans W, Thompson A, Tripathy D, Mittendorf E. Abstract OT2-01-14: Triple-negative first-line study: Neoadjuvant trial of nab-paclitaxel and atezolizumab, a PD-L1 inhibitor, in patients with triple negative breast cancer (TNBC) (NCT02530489) Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-Ot2-01-14  1
2017 Fueyo J, Gomez-Manzano C, Villalobos P, Rodriguez-Canales J, Mino B, Wistuba I, Hess K, Alonso M, Tejada S, Diez-Valle R, Ewald B, Tufaro F, Lang F. Abstract LB-235: Delta-24-RGD oncolytic adenovirus treatment downmodulates the key regulator of T-cell exhaustion TIM3 in malignant gliomas Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-235  1
2017 Sen S, Hess K, Hong D, Naing A, Piha-Paul S, Janku F, Fu S, Liu H, Jiang Y, Khanji R, Karp D, Tsimberidou A, Tannir N, Meric-Bernstam F, Subbiah V. Abstract 3291: Development of a novel prognostic scoring system for patient selection in immune checkpoint inhibitor phase 1 clinical trials Cancer Research. 77: 3291-3291. DOI: 10.1158/1538-7445.Am2017-3291  1
2017 Fueyo J, Gomez-Manzano C, Villalobos P, Rodriguez-Canales J, Wistuba I, Hess KR, Alonso MM, Tejada S, Valle RD, Ewald B, Tufaro F, Lang F. ATIM-08. IMMUNOMARKERS IN THE DNX-2401 (DELTA-24-RGD) ONCOLYTIC VIRUS PHASE I CLINICAL TRIAL Neuro-Oncology. 19: vi27-vi27. DOI: 10.1093/NEUONC/NOX168.104  0.01
2017 Damodaran S, Symmans F, Helgason T, Mittendorf E, Tripathy D, Hess K, Litton J, Moulder S. A phase II trial of mirvetuximab soravtansine in patients with localized triple-negative breast cancer (TNBC) with tumors predicted insensitive to standard neoadjuvant chemotherapy (NACT) including a lead-in cohort to establish activity in patients with metastatic TNBC Annals of Oncology. 28: v106. DOI: 10.1093/ANNONC/MDX365.083  0.01
2017 Abderrahman B, Ibrahim N, Hess K. Statistical model to predict brain metastasis risk in patients with early-stage breast cancer Annals of Oncology. 28: v48. DOI: 10.1093/annonc/mdx362.011  0.01
2017 Welsh J, Tang C, de Groot P, Naing A, Raju U, Shaaban S, Chang J, Cushman T, Heymach J, Dadu R, Cabanillas M, Hess K, Massarelli E, Subbiah V, Fu S, et al. Phase 2 5-Arm Trial of Ipilimumab Plus Lung or Liver Stereotactic Radiation for Patients with Advanced Malignancies International Journal of Radiation Oncology*Biology*Physics. 99: 1315. DOI: 10.1016/J.IJROBP.2017.09.012  0.01
2017 Tang C, de Groot P, Hess K, Shabaan S, Gomez D, Chang J, Lin S, Paraskevopoulos T, Raju U, Simon G, Papadimitrakopoulou V, Liao Z, Fossella F, Glisson B, Komaki R, et al. Phase 1 Study of Pembrolizumab and Stereotactic or Hypofractionated Radiation for Metastatic Non–small Cell Lung Cancer International Journal of Radiation Oncology*Biology*Physics. 99: S160-S161. DOI: 10.1016/J.IJROBP.2017.06.370  0.01
2016 Rao G, Ahmed S, Hess K, Mahajan A. 215 Postoperative Stereotactic Radiosurgery vs Observation for Completely Resected Brain Metastases: Results of a Prospective Randomized Study. Neurosurgery. 63: 184. PMID 28175447 DOI: 10.1227/01.neu.0000489784.83922.17  1
2016 Tannir NM, Williams JL, Hess KR, Frisbee-Hume S, House HL, Fossella FV, Lim ZD, Lopez G, Reddy AS, Azhar A, Wong A, Patel SM, Kaseb AO, Hwu WJ, Lu Z, et al. Effects of high-dose Asian ginseng (Panax ginseng) to improve cancer-related fatigue: Results of a double-blind, placebo-controlled randomized controlled trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 209. PMID 28156612 DOI: 10.1200/jco.2016.34.26_suppl.209  1
2016 Shahar T, Rozovski U, Hess KR, Hossain A, Gumin J, Gao F, Fuller GN, Goodman L, Sulman EP, Lang FF. Percentage of mesenchymal stem cells in high-grade glioma tumor samples correlates with patient survival. Neuro-Oncology. PMID 27994067 DOI: 10.1093/neuonc/now239  1
2016 Sneige N, Hess KR, Multani AS, Gong Y, Ibrahim NK. Prognostic significance of equivocal human epidermal growth factor receptor 2 results and clinical utility of alternative chromosome 17 genes in patients with invasive breast cancer: A cohort study. Cancer. PMID 27893937 DOI: 10.1002/cncr.30460  1
2016 Basho RK, Gilcrease M, Murthy RK, Helgason T, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton JK, Chavez-MacGregor M, Ibrahim NK, Murray JL, Koenig KB, et al. Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. Jama Oncology. PMID 27893038 DOI: 10.1001/Jamaoncol.2016.5281  1
2016 Bilen MA, Hess KR, Campbell MT, Wang J, Broaddus RR, Karam JA, Ward JF, Wood CG, Choi SL, Rao P, Zhang M, Naing A, General R, Cauley DH, Lin SH, et al. Intratumoral heterogeneity and chemoresistance in nonseminomatous germ cell tumor of the testis. Oncotarget. PMID 27861143 DOI: 10.18632/oncotarget.13380  1
2016 Tang C, Hess KR, Sanders D, Davis SE, Buzdar AU, Kurzrock R, Lee JJ, Meric-Bernstam F, Hong DS. Modifying the clinical research infrastructure at a dedicated clinical trials unit: assessment of trial development, activation, and participant accrual. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27852698 DOI: 10.1158/1078-0432.Ccr-16-1936  1
2016 Huang ML, Hess K, Candelaria RP, Eghtedari M, Adrada BE, Sneige N, Fornage BD. Comparison of the accuracy of US-guided biopsy of breast masses performed with 14-gauge, 16-gauge and 18-gauge automated cutting needle biopsy devices, and review of the literature. European Radiology. PMID 27844099 DOI: 10.1007/S00330-016-4651-5  1
2016 Kinahan H, Maiti A, Hess K, Dempsey J, Beatty L, Baldwin S, Hong DS, Naing A, Fu S, Tsimberidou AM, Piha-Paul S, Janku F, Karp D, Reddy S, Yennu S, et al. Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit. Oncology. PMID 27802448 DOI: 10.1159/000449505  1
2016 Roszik J, Haydu LE, Hess KR, Oba J, Joon AY, Siroy AE, Karpinets TV, Stingo FC, Baladandayuthapani V, Tetzlaff MT, Wargo JA, Chen K, Forget MA, Haymaker CL, Chen JQ, et al. Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. Bmc Medicine. 14: 168. PMID 27776519 DOI: 10.1186/S12916-016-0705-4  1
2016 Subbiah V, Hess KR, Khawaja MR, Wagner MJ, Tang C, Naing A, Fu S, Janku F, Piha-Paul S, Tsimberidou AM, Herzog CE, Ludwig JA, Patel S, Ravi V, Benjamin RS, et al. Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Scientific Reports. 6: 35448. PMID 27748430 DOI: 10.1038/srep35448  1
2016 Bupathi M, Hajjar J, Bean S, Fu S, Hong D, Karp D, Stephen B, Hess K, Meric-Bernstam F, Naing A. Incidence of infusion reactions to anti-neoplastic agents in early phase clinical trials: The MD Anderson Cancer Center experience. Investigational New Drugs. PMID 27687047 DOI: 10.1007/S10637-016-0395-Y  1
2016 Mahajan A, Ahmed S, Li J, McAleer MF, Weinberg J, Brown PD, Prabhu S, Lang FF, McGovern SL, McCutcheon IE, Heimberger A, Sulman EP, Ghia AJ, Ferguson S, Hess K, et al. Postoperative Stereotactic Radiosurgery Versus Observation for Completely Resected Brain Metastases: Results of a Prospective Randomized Study. International Journal of Radiation Oncology, Biology, Physics. 96: S2. PMID 27675774 DOI: 10.1016/J.Ijrobp.2016.06.022  1
2016 Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, et al. Ipilimumab with stereotactic ablative radiation therapy: Phase I results and immunologic correlates from peripheral T-cells. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27649551 DOI: 10.1158/1078-0432.Ccr-16-1432  1
2016 Subbiah IM, Wheler JJ, Hess KR, Hong DS, Naing A, Fu S, Kurzrock R, Tsimberidou AM. Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD Anderson Cancer Center. International Journal of Cancer. PMID 27599876 DOI: 10.1002/Ijc.30417  1
2016 Livingston JA, Hess KR, Naing A, Hong DS, Patel S, Benjamin RS, Ludwig JA, Conley A, Herzog CE, Anderson P, Meric-Bernstam F, Kurzrock R, Subbiah V. Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget. PMID 27486883 DOI: 10.18632/Oncotarget.10910  1
2016 Hui D, Cerana MA, Park M, Hess K, Bruera E. Impact of Oncologists' Attitudes Toward End-of-Life Care on Patients' Access to Palliative Care. The Oncologist. PMID 27412394 DOI: 10.1634/Theoncologist.2016-0090  1
2016 Yuan Y, Hess KR, Hilsenbeck SG, Gilbert MR. Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27407096 DOI: 10.1158/1078-0432.Ccr-16-0592  1
2016 Rao G, Ahmed S, Hess K, Mahajan A. 215 Postoperative Stereotactic Radiosurgery vs Observation for Completely Resected Brain Metastases: Results of a Prospective Randomized Study. Neurosurgery. 63: 184. PMID 27399494 DOI: 10.1227/01.Neu.0000489784.83922.17  1
2016 Noren DP, Long BL, Norel R, Rrhissorrakrai K, Hess K, Hu CW, Bisberg AJ, Schultz A, Engquist E, Liu L, Lin X, Chen GM, Xie H, Hunter GA, Boutros PC, et al. A Crowdsourcing Approach to Developing and Assessing Prediction Algorithms for AML Prognosis. Plos Computational Biology. 12: e1004890. PMID 27351836 DOI: 10.1371/Journal.Pcbi.1004890  1
2016 Raj SD, Amer AM, Garg N, Krishnamurthy S, Hess KR, Park YM, Moseley T, Whitman GJ. Incidental Suspicious Regional Lymph Nodes on Breast Sonography: Is Sampling Necessary? Current Problems in Diagnostic Radiology. PMID 27338308 DOI: 10.1067/J.Cpradiol.2016.05.005  1
2016 Bilen MA, Patel A, Hess KR, Munoz J, Busaidy NL, Wheler JJ, Janku F, Falchook GS, Hong DS, Meric-Bernstam F, Habra MA, Naing A. Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials. Cancer Chemotherapy and Pharmacology. PMID 27286994 DOI: 10.1007/s00280-016-3073-z  1
2016 Phillips LM, Zhou X, Cogdell DE, Chua CY, Huisinga A, Hess KR, Fuller GN, Zhang W. Glioma progression is mediated by an addiction to aberrant IGFBP2 expression and can be blocked using anti-IGFBP2 strategies. The Journal of Pathology. PMID 27125842 DOI: 10.1002/path.4734  1
2016 Falchook GS, Rady P, Konopinski JC, Busaidy N, Hess K, Hymes S, Nguyen HP, Prieto VG, Bustinza-Linares E, Lin Q, Parkhurst KL, Hong DS, Sherman S, Tyring SK, Kurzrock R. Merkel cell polyomavirus and human papilloma virus in proliferative skin lesions arising in patients treated with BRAF inhibitors. Archives of Dermatological Research. PMID 27098388 DOI: 10.1007/S00403-016-1650-Y  1
2016 Tang C, Liao Z, Hess K, Chance WW, Zhuang Y, Jensen G, Xu T, Komaki R, Gomez DR. Prognosis and predictors of site of first metastasis after definitive radiation therapy for non-small cell lung cancer. Acta Oncologica (Stockholm, Sweden). 1-7. PMID 27055359 DOI: 10.3109/0284186X.2016.1154602  1
2016 Mahar AL, Compton C, Halabi S, Hess KR, Gershenwald JE, Scolyer RA, Groome PA. Critical Assessment of Clinical Prognostic Tools in Melanoma. Annals of Surgical Oncology. PMID 27052645 DOI: 10.1245/s10434-016-5212-5  1
2016 Tu SM, Bilen MA, Hess KR, Broaddus RR, Kopetz S, Wei C, Pagliaro LC, Karama JA, Ward JF, Wood CG, Rao P, Tu ZH, General R, Chen AH, Nieto YL, et al. Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer. PMID 27018785 DOI: 10.1002/cncr.29996  1
2016 Shingu T, Holmes L, Henry V, Wang Q, Latha K, Gururaj AE, Gibson LA, Doucette T, Lang FF, Rao G, Yuan L, Sulman EP, Farrell NP, Priebe W, Hess KR, et al. Suppression of RAF/MEK or PI3K synergizes cytotoxicity of receptor tyrosine kinase inhibitors in glioma tumor-initiating cells. Journal of Translational Medicine. 14: 46. PMID 26861698 DOI: 10.1186/S12967-016-0803-2  1
2016 Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, Blackwell KL, Liu MC, Lowe A, Agar NY, Ryabin N, et al. Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26834058 DOI: 10.1200/JCO.2015.63.0343  1
2016 Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum S, Wang J, Manyam G, Zoppoli P, Ling S, ... ... Hess K, et al. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma. Cell. 164: 550-563. PMID 26824661 DOI: 10.1016/J.Cell.2015.12.028  1
2016 Kattan MW, Hess KR, Amin MB, Lu Y, Moons KG, Gershenwald JE, Gimotty PA, Guinney JH, Halabi S, Lazar AJ, Mahar AL, Patel T, Sargent DJ, Weiser MR, Compton C, et al. American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. Ca: a Cancer Journal For Clinicians. PMID 26784705 DOI: 10.3322/Caac.21339  1
2016 McQuade JL, Haydu LE, Frankian S, Spencer C, Long GV, Grob JJ, Lane SR, Legenne P, Flaherty K, Hwu P, Hess KR, Davies MA. The impact of obesity on outcomes in metastatic melanoma (MM) patients (pts) treated with dabrafenib and trametinib. Journal of Clinical Oncology. 34: 9566-9566. DOI: 10.1200/JCO.2016.34.15_SUPPL.9566  0.01
2016 Cascone T, Hess KR, Piha-Paul SA, Hong DS, Subbiah IM, Bhatt T, Fu S, Naing A, Janku F, Karp DD, Meric-Bernstam F, Heymach J, Subbiah V. Safety, toxicity and activity of multi-kinase inhibitor vandetanib in combination with everolimus in advanced solid tumors. Journal of Clinical Oncology. 34: 9073-9073. DOI: 10.1200/JCO.2016.34.15_SUPPL.9073  0.01
2016 Cascone T, Subbiah V, Hess KR, Nelson S, Nilsson MB, Subbiah IM, Ali SM, Carbone DP, Salgia R, Owonikoko TK, Meric-Bernstam F, Doebele RC, Heymach J, trial TCEct. Significant systemic and CNS activity of RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with advanced NSCLC with RET fusion. Journal of Clinical Oncology. 34: 9069-9069. DOI: 10.1200/Jco.2016.34.15_Suppl.9069  1
2016 Tang C, Welsh JW, Groot Pd, Massarelli E, Chang JY, Hess KR, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp DD, Gomez DR, Komaki R, Sharma P, et al. Phase I trial combining ipilimumab + high dose stereotactic radiation: Results and serum immune correlates. Journal of Clinical Oncology. 34: 3022-3022. DOI: 10.1200/Jco.2016.34.15_Suppl.3022  1
2016 Ager C, Reilley M, Nicholas C, Bartkowiak T, Jaiswal A, Curran M, Albershardt TC, Bajaj A, Archer JF, Reeves RS, Ngo LY, Berglund P, ter Meulen J, Denis C, Ghadially H, ... ... Hess KR, et al. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two Journal For Immunotherapy of Cancer. 4. DOI: 10.1186/S40425-016-0173-6  1
2016 Basho RK, Gilcrease M, Murthy RK, Helgason T, Booser DJ, Karp DD, Meric-Bernstam F, Hess KR, Herbrich SM, Valero V, Albarracin C, Litton J, Chavez-MacGregor M, Ibrahim NK, Murray JL, et al. Abstract 2273: Targeting the PI3K/AKT/mTOR pathway for the treatment of metaplastic breast cancer: Does location of PIK3CA mutation or histology affect response Cancer Research. 76: 2273-2273. DOI: 10.1158/1538-7445.Am2016-2273  1
2016 Björnsson G, Hess K. Corporate Crocodile Tears? On the Reactive Attitudes of Corporate Agents Philosophy and Phenomenological Research. DOI: 10.1111/phpr.12260  1
2016 Hu X, Martinez-Ledesma E, Zheng S, Kim H, Barthel F, Jiang T, R Hess K, Verhaak R. TMOD-31. AN INFLAMMATION RESPONSE GENE SIGNATURE IS ASSOCIATED WITH PROGNOSIS OF GLIOMA PATIENTS WITH 1p/19q CO-DELETION TUMORS Neuro-Oncology. 18: vi213-vi213. DOI: 10.1093/NEUONC/NOW212.901  0.01
2016 Moulder S, Litton J, Mittendorf E, Yang W, Ueno N, Hess K, Valero V, Murthy R, Ibrahim N, Lim B, Arun B, Thompson A, Piwnica-Worms H, Tripathy D, Symmans W. Improving outcomes in triple-negative breast cancer (TNBC) using molecular characterization and diagnostic imaging to identify and treat chemo-insensitive disease Annals of Oncology. 27: vi67. DOI: 10.1093/Annonc/Mdw364.76  0.01
2016 Litton J, Scoggins M, Ramirez D, Murthy R, Whitman G, Hess K, Adrada B, Moulder S, Barcenas C, Valero V, Booser D, Gomez JS, Mills G, Piwnica-Worms H, Arun B. A pilot study of neoadjuvant talazoparib for early-stage breast cancer patients with a BRCA mutation Annals of Oncology. 27: vi46. DOI: 10.1093/Annonc/Mdw364.10  0.01
2016 Hess K. Power to the Virtuous?: Civic culture in the changing digital terrain Journalism Studies. 1-10. DOI: 10.1080/1461670X.2016.1154796  1
2016 Fujii T, Colen R, Bilen M, Hess K, Hajjar J, Suarez-Almazor M, Alshawa A, Hong D, Stephen B, Janku F, Subbiah V, Kato S, Karp D, Piha-Paul S, Tsimberidou A, et al. Incidence of immune-related adverse events in patients who received immunotherapy and radiographic analysis to predict pneumonitis European Journal of Cancer. 69. DOI: 10.1016/S0959-8049(16)32883-0  1
2016 George G, Buford A, Hess K, Piha-Paul S, Zinner R, Subbiah V, Iwuanyanwu E, Cleeland C, Meric-Bernstam F, Bernstam E, Hong D. Cancer-related internet use in patients with advanced cancer in a phase I clinical trials clinic European Journal of Cancer. 69. DOI: 10.1016/S0959-8049(16)32782-4  1
2016 Tang C, Hess K, Sanders D, Davis S, Kurzrock R, Lee J, Meric Bernstam F, Hong D. Efficient clinical research infrastructure and trial performance: Assessment of a dedicated clinical trials unit within an academic cancer center European Journal of Cancer. 69: S64. DOI: 10.1016/S0959-8049(16)32779-4  0.01
2016 Hess K. The Hochschild complex of a twisting cochain Journal of Algebra. 451: 302-356. DOI: 10.1016/j.jalgebra.2015.11.040  1
2015 Li YM, Suki D, Hess K, Sawaya R. The influence of maximum safe resection of glioblastoma on survival in 1229 patients: Can we do better than gross-total resection? Journal of Neurosurgery. 1-12. PMID 26495941 DOI: 10.3171/2015.5.Jns142087  1
2015 Liu X, George GC, Tsimberidou AM, Naing A, Wheler JJ, Kopetz S, Fu S, Piha-Paul SA, Eng C, Falchook GS, Janku F, Garrett C, Karp D, Kurzrock R, Zinner R, ... Hess K, et al. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. Bmc Cancer. 15: 713. PMID 26474549 DOI: 10.1186/S12885-015-1701-3  1
2015 Delpech Y, Bashour SI, Lousquy R, Rouzier R, Hess K, Coutant C, Barranger E, Esteva FJ, Ueno NT, Pusztai L, Ibrahim NK. Clinical nomogram to predict bone-only metastasis in patients with early breast carcinoma. British Journal of Cancer. 113: 1003-9. PMID 26393887 DOI: 10.1038/Bjc.2015.308  1
2015 Asare EA, Liu L, Hess KR, Gordon EJ, Paruch JL, Palis B, Dahlke AR, McCabe R, Cohen ME, Winchester DP, Bilimoria KY. Development of a model to predict breast cancer survival using data from the National Cancer Data Base. Surgery. PMID 26365950 DOI: 10.1016/j.surg.2015.08.006  1
2015 Shaitelman SF, Tereffe W, Dogan BE, Hess KR, Caudle AS, Valero V, Stauder MC, Krishnamurthy S, Candelaria RP, Strom EA, Woodward WA, Hunt KK, Buchholz TA, Whitman GJ. Role of Ultrasonography of Regional Nodal Basins in Staging Triple-Negative Breast Cancer and Implications For Local-Regional Treatment. International Journal of Radiation Oncology, Biology, Physics. 93: 102-10. PMID 26279028 DOI: 10.1016/J.Ijrobp.2015.05.015  1
2015 Hui D, Hess K, Santos RD, Chisholm G, Bruera E. A diagnostic model for impending death in cancer patients: Preliminary report. Cancer. 121: 3914-21. PMID 26218612 DOI: 10.1002/Cncr.29602  1
2015 Subbiah IM, Falchook GS, Kaseb AO, Hess KR, Tsimberidou AM, Fu S, Subbiah V, Hong DS, Naing A, Piha-Paul SA, Akmal O, Janku F, Kurzrock R. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. Oncotarget. 6: 28453-62. PMID 26164085 DOI: 10.18632/Oncotarget.4601  1
2015 Qi Y, Liu X, Liu CG, Wang B, Hess KR, Symmans WF, Shi W, Pusztai L. Reproducibility of Variant Calls in Replicate Next Generation Sequencing Experiments. Plos One. 10: e0119230. PMID 26136146 DOI: 10.1371/journal.pone.0119230  1
2015 Tang C, Hess K, Bishop AJ, Pan HY, Christensen EN, Yang JN, Tannir N, Amini B, Tatsui C, Rhines L, Brown P, Ghia A. Creation of a Prognostic Index for Spine Metastasis to Stratify Survival in Patients Treated With Spinal Stereotactic Radiosurgery: Secondary Analysis of Mature Prospective Trials. International Journal of Radiation Oncology, Biology, Physics. PMID 26130231 DOI: 10.1016/j.ijrobp.2015.04.050  1
2015 Busaidy NL, LoRusso P, Lawhorn K, Hess KR, Habra MA, Fu S, Hong DS, Chen HX, Doyle LA, Kurzrock R, Naing A. The Prevalence and Impact of Hyperglycemia and Hyperlipidemia in Patients With Advanced Cancer Receiving Combination Treatment With the Mammalian Target of Rapamycin Inhibitor Temsirolimus and Insulin Growth Factor-Receptor Antibody Cixutumumab. The Oncologist. 20: 737-41. PMID 26054632 DOI: 10.1634/Theoncologist.2015-0065  1
2015 Phan AT, Halperin DM, Chan JA, Fogelman DR, Hess KR, Malinowski P, Regan E, Ng CS, Yao JC, Kulke MH. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study. The Lancet. Oncology. 16: 695-703. PMID 25956795 DOI: 10.1016/S1470-2045(15)70136-1  1
2015 Dasari A, Phan A, Gupta S, Rashid A, Yeung SC, Hess K, Chen H, Tarco E, Chen H, Wei C, Anh-Do K, Halperin D, Meric-Bernstam F, Yao J. Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors. Endocrine-Related Cancer. 22: 431-41. PMID 25900182 DOI: 10.1530/Erc-15-0002  1
2015 Melguizo-Gavilanes I, Bruner JM, Guha-Thakurta N, Hess KR, Puduvalli VK. Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard? Journal of Neuro-Oncology. 123: 141-50. PMID 25894594 DOI: 10.1007/s11060-015-1774-5  1
2015 Tsimberidou AM, Said R, Culotta K, Wistuba I, Jelinek J, Fu S, Falchook G, Naing A, Piha-Paul S, Zinner R, Siddik ZH, He G, Hess K, Stewart DJ, Kurzrock R, et al. Phase I study of azacitidine and oxaliplatin in patients with advanced cancers that have relapsed or are refractory to any platinum therapy. Clinical Epigenetics. 7: 29. PMID 25806091 DOI: 10.1186/S13148-015-0065-5  1
2015 Shen Q, Sahin AA, Hess KR, Suki D, Aldape KD, Sawaya R, Ibrahim NK. Breast cancer with brain metastases: clinicopathologic features, survival, and paired biomarker analysis. The Oncologist. 20: 466-73. PMID 25802405 DOI: 10.1634/Theoncologist.2014-0107  1
2015 Pan HY, Morani A, Wang WL, Hess KR, Paulino AC, Ludwig JA, Lin PP, Daw NC, Mahajan A. Prognostic factors and patterns of relapse in ewing sarcoma patients treated with chemotherapy and r0 resection. International Journal of Radiation Oncology, Biology, Physics. 92: 349-57. PMID 25772182 DOI: 10.1016/j.ijrobp.2015.01.022  1
2015 Naing A, Dalal S, Abdelrahim M, Wheler J, Hess K, Fu S, Hong DS, Janku F, Falchook GS, Ilustre A, Ouyang F, Kurzrock R. Olanzapine for cachexia in patients with advanced cancer: an exploratory study of effects on weight and metabolic cytokines. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. PMID 25680763 DOI: 10.1007/S00520-015-2625-9  1
2015 Fu S, Hou MM, Naing A, Janku F, Hess K, Zinner R, Subbiah V, Hong D, Wheler J, Piha-Paul S, Tsimberidou A, Karp D, Araujo D, Kee B, Hwu P, et al. Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 26: 1012-8. PMID 25669829 DOI: 10.1093/Annonc/Mdv066  1
2015 Yao JC, Phan AT, Hess K, Fogelman D, Jacobs C, Dagohoy C, Leary C, Xie K, Ng CS. Perfusion computed tomography as functional biomarker in randomized run-in study of bevacizumab and everolimus in well-differentiated neuroendocrine tumors. Pancreas. 44: 190-7. PMID 25426617 DOI: 10.1097/Mpa.0000000000000255  1
2015 Hess K. The vulnerable blood: Coagulation and clot structure in diabetes mellitus Hamostaseologie. 35: 25-33. PMID 25418205  1
2015 Penas-Prado M, Hess KR, Fisch MJ, Lagrone LW, Groves MD, Levin VA, De Groot JF, Puduvalli VK, Colman H, Volas-Redd G, Giglio P, Conrad CA, Salacz ME, Floyd JD, Loghin ME, et al. Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. Neuro-Oncology. 17: 266-73. PMID 25239666 DOI: 10.1093/Neuonc/Nou155  1
2015 Jardim DL, de Melo Gagliato D, Falchook G, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Tannir N, Corn P, Tang C, Hess K, Roy-Chowdhuri S, Kurzrock R, et al. MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. Clinical Genitourinary Cancer. 13: e19-26. PMID 25087088 DOI: 10.1016/J.Clgc.2014.06.017  1
2015 Subbiah IM, Falchook GS, Kaseb AO, Hess KR, Tsimberidou AM, Fu S, Subbiah V, Hong DS, Naing A, Sarina APP, Akmal O, Janku F, Kurzrock R. Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: An analysis of targeted therapy phase 1 trials Oncotarget. 6: 28453-28462. DOI: 10.18632/oncotarget.4601  1
2015 Goldstein JB, Tang C, Hong DS, Subbiah V, Janku F, Hess KR, Fu S, Karp DD, Naing A, Tsimberidou AM, Wheler JJ, Zinner R, Javle MM, Varadhachary GR, Wolff RA, et al. Evolution of phase 1 trials for patients with advanced pancreatic cancer: An update on the experience from MD Anderson Cancer Center. Journal of Clinical Oncology. 33: 320-320. DOI: 10.1200/jco.2015.33.3_suppl.320  0.01
2015 Subbiah V, Kawedia JD, Christensen A, Hess KR, Patel K, Wood E, Bitar RD, Daw NC. Comparison of adult oncology phase 1 trials to pediatric oncology phase 1 trials of targeted therapies. Journal of Clinical Oncology. 33: 2581-2581. DOI: 10.1200/JCO.2015.33.15_SUPPL.2581  0.01
2015 Penas-Prado M, Hess KR, Levin VA, De Groot JF, Colman H, Groves MD, Conrad CA, Loghin ME, Hunter K, Gilbert MR, Yung WKA, Puduvalli VK. Phase I study of vorinostat combined with isotretinoin and temozolomide in adults with recurrent malignant gliomas. Journal of Clinical Oncology. 33: 2039-2039. DOI: 10.1200/Jco.2015.33.15_Suppl.2039  0.01
2015 French JT, Hess KR, Liu DD, Raghav KPS, Hortobagyi GN, Arun B, Valero V, Ueno NT, Alvarez RH, Woodward WA, Debeb BG, Moulder SL, Lim B, Tripathy D, Ibrahim NK. Development of CNS metastasis and subsequent survival in patients with inflammatory breast cancer. Journal of Clinical Oncology. 33: 1586-1586. DOI: 10.1200/Jco.2015.33.15_Suppl.1586  1
2015 Wagner M, Hess KR, Hong DS, Tang C, Naing A, Fu S, Janku F, Piha-Paul SA, Zinner R, Wheler JJ, Tsimberidou AM, Patel S, Somaiah N, Ravi V, Benjamin RS, et al. Validation of the Royal Marsden Hospital (RMH) prognostic score in 100 patients with advanced sarcoma enrolled in early phase clinical trials at a major cancer center. Journal of Clinical Oncology. 33: 10558-10558. DOI: 10.1200/JCO.2015.33.15_SUPPL.10558  0.01
2015 Shingu T, Holmes L, Henry V, Latha K, Gururaj AE, Gibson LA, Doucette T, Lang FF, Rao G, Yuan L, Sulman EP, Farrell NP, Priebe W, Hess KR, Wang YA, et al. Abstract 3483: Synergistic combination therapy with molecular targeted drugs in glioma stem-like cells Cancer Research. 75: 3483-3483. DOI: 10.1158/1538-7445.Am2015-3483  1
2015 Hu X, Martinez E, Zheng S, Barthel F, Jiang T, Hess K, Verhaak R. GENO-18A 35 GENES SIGNATURE FOR PREDICTING OUTCOME IN GLIOMA PATIENTS WITH 1p/19q CODEL Neuro-Oncology. 17: v95.2-v95. DOI: 10.1093/Neuonc/Nov215.18  0.01
2015 Hess K. Making Connections: “Mediated” social capital and the small-town press Journalism Studies. 16: 482-496. DOI: 10.1080/1461670X.2014.922293  1
2014 Hess K. How I do it: monthly quality review - the tools I use Journal of Registry Management. 41: 160-163. PMID 25974982  1
2014 Falchook GS, Naing A, Wheler JJ, Tsimberidou AM, Zinner R, Hong DS, Fu S, Piha-Paul SA, Janku F, Hess KR, Bastida C, Kurzrock R. Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. Oncoscience. 1: 540-9. PMID 25594061  1
2014 Hu Y, Gao H, Vo C, Ke C, Pan F, Yu L, Siegel E, Hess KR, Linskey ME, Zhou YH. Anti-EGFR function of EFEMP1 in glioma cells and patient prognosis. Oncoscience. 1: 205-15. PMID 25594013  1
2014 Tang C, Fontes Jardim DL, Falchook GS, Hess K, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, De Melo Galgiato D, Westin SN, Meric-Bernstam F, Kurzrock R, Hong DS. MET nucleotide variations and amplification in advanced ovarian cancer: characteristics and outcomes with c-Met inhibitors. Oncoscience. 1: 5-13. PMID 25593979  1
2014 Corrales-Medina FF, Herzog C, Hess K, Egas-Bejar D, Hong DS, Falchook G, Anderson P, Nunez C, Huh WW, Naing A, Tsimberidou AM, Wheler J, Paul SP, Janku F, Kleinerman ES, et al. Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experience. Oncoscience. 1: 522-30. PMID 25587555 DOI: 10.18632/oncoscience.68  1
2014 Falchook GS, Wheler JJ, Naing A, Jackson EF, Janku F, Hong D, Ng CS, Tannir NM, Lawhorn KN, Huang M, Angelo LS, Vishwamitra D, Hess K, Howard AN, Parkhurst KL, et al. Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: a phase I trial of bortezomib plus bevacizumab. Oncotarget. 5: 10280-92. PMID 25373733 DOI: 10.18632/Oncotarget.2163  1
2014 Jardim DL, Tang C, Gagliato Dde M, Falchook GS, Hess K, Janku F, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Holla V, Li MM, Roy-Chowdhuri S, Luthra R, et al. Analysis of 1,115 patients tested for MET amplification and therapy response in the MD Anderson Phase I Clinic. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 6336-45. PMID 25326232 DOI: 10.1158/1078-0432.Ccr-14-1293  1
2014 Tang C, Hess K, Jardim DL, Gagliato Dde M, Tsimberidou AM, Falchook G, Fu S, Janku F, Naing A, Piha-Paul S, Subbiah V, Wheler J, Zinner RG, Kurzrock R, Ellis LM, et al. Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 5956-63. PMID 25316815 DOI: 10.1158/1078-0432.Ccr-14-1582  1
2014 Said R, Ye Y, Falchook GS, Janku F, Naing A, Zinner R, Blumenschein GR, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Kurzrock R, Palmer GA, Aldape K, Hess KR, et al. Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. Oncotarget. 5: 8937-46. PMID 25313136 DOI: 10.18632/ONCOTARGET.2339  1
2014 de Melo Gagliato D, Jardim DL, Falchook G, Tang C, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Hess K, Roy-Chowdhuri S, Moulder S, Gonzalez-Angulo AM, Meric-Bernstam F, et al. Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit. Clinical Breast Cancer. 14: 468-74. PMID 25065564 DOI: 10.1016/J.Clbc.2014.06.001  1
2014 Said R, Ye Y, Hong DS, Janku F, Fu S, Naing A, Wheler JJ, Kurzrock R, Thomas C, Palmer GA, Hess KR, Aldape K, Tsimberidou AM. Characteristics and survival of patients with advanced cancer and p53 mutations. Oncotarget. 5: 3871-9. PMID 25003695 DOI: 10.18632/Oncotarget.2004  1
2014 Hess KC, Liu J, Manfredi G, Mühlschlegel FA, Buck J, Levin LR, Barrientos A. A mitochondrial CO2-adenylyl cyclase-cAMP signalosome controls yeast normoxic cytochrome c oxidase activity. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 28: 4369-80. PMID 25002117 DOI: 10.1096/Fj.14-252890  1
2014 Hess K. Emergency response protection against hypothermia Occupational Health &Amp; Safety (Waco, Tex.). 83: 22. PMID 24984418  1
2014 Abbruzzese JL, Hess KR. New option for the initial management of metastatic pancreatic cancer? Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 2405-7. PMID 24982449 DOI: 10.1200/JCO.2013.54.4155  1
2014 Yuan Y, Van Allen EM, Omberg L, Wagle N, Amin-Mansour A, Sokolov A, Byers LA, Xu Y, Hess KR, Diao L, Han L, Huang X, Lawrence MS, Weinstein JN, Stuart JM, et al. Assessing the clinical utility of cancer genomic and proteomic data across tumor types. Nature Biotechnology. 32: 644-52. PMID 24952901 DOI: 10.1038/Nbt.2940  1
2014 Bilen MA, Durand JB, McQuinn L, Hess KR, Fu S, Falchook GS, Hong DS, Wheler JJ, Said R, Ewer MS, Kurzrock R, Naing A. Evaluation of a novel blood pressure scoring method and its association with clinical response in cancer patients treated with anti-vascular endothelial growth factor therapy. Investigational New Drugs. 32: 717-22. PMID 24764123 DOI: 10.1007/S10637-014-0104-7  1
2014 Jardim DL, de Melo Gagliato D, Falchook GS, Janku F, Zinner R, Wheler JJ, Subbiah V, Piha-Paul SA, Fu S, Murphy MB, Ajani J, Tang C, Hess K, Hamilton SR, Roy-Chowdhuri S, et al. MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. Oncotarget. 5: 1837-45. PMID 24742823 DOI: 10.18632/Oncotarget.1828  1
2014 Dabaja BS, Hess K, Shihadeh F, Podoloff DA, Medeiros LJ, Mawlawi O, Arzu I, Oki Y, Hagemeister FB, Fayad LE, Reed VK, Kedir A, Wogan CF, Rodriguez A. Positron emission tomography/computed tomography findings during therapy predict outcome in patients with diffuse large B-cell lymphoma treated with chemotherapy alone but not in those who receive consolidation radiation. International Journal of Radiation Oncology, Biology, Physics. 89: 384-91. PMID 24721592 DOI: 10.1016/J.Ijrobp.2014.02.015  1
2014 Murthy RK, Varma A, Mishra P, Hess KR, Young E, Murray JL, Koenig KH, Moulder SL, Melhem-Bertrandt A, Giordano SH, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer. Cancer. 120: 1932-8. PMID 24677057 DOI: 10.1002/cncr.28689  1
2014 Liu X, Lorusso P, Mita M, Piha-Paul S, Hong DS, Fu S, McQuinn L, Asatiani E, Doyle LA, Chen HX, Hess KR, Kurzrock R, Naing A. Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. The Oncologist. 19: 426-8. PMID 24668327 DOI: 10.1634/Theoncologist.2013-0231  1
2014 Anderson MD, Hamza MA, Hess KR, Puduvalli VK. Implications of bevacizumab discontinuation in adults with recurrent glioblastoma. Neuro-Oncology. 16: 823-8. PMID 24596117 DOI: 10.1093/neuonc/nou021  1
2014 Jardim DL, Wheler JJ, Hess K, Tsimberidou AM, Zinner R, Janku F, Subbiah V, Naing A, Piha-Paul SA, Westin SN, Roy-Chowdhuri S, Meric-Bernstam F, Hong DS. FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. Plos One. 9: e89388. PMID 24586741 DOI: 10.1371/Journal.Pone.0089388  1
2014 Tsimberidou AM, Adamopoulos AM, Ye Y, Piha-Paul S, Janku F, Fu S, Hong D, Falchook GS, Naing A, Wheler J, Fortier A, Kurzrock R, Hess KR. Phase I clinical trial of bendamustine and bevacizumab for patients with advanced cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 12: 194-203. PMID 24586081 DOI: 10.6004/Jnccn.2014.0020  1
2014 Thompson LM, Eckmann K, Boster BL, Hess KR, Michaud LB, Esteva FJ, Hortobágyi GN, Barnett CM. Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving trastuzumab. The Oncologist. 19: 228-34. PMID 24536030 DOI: 10.1634/theoncologist.2013-0286  1
2014 Hess KR, Levin VA. Getting more out of survival data by using the hazard function. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 1404-9. PMID 24501392 DOI: 10.1158/1078-0432.CCR-13-2125  1
2014 Said R, Banchs J, Wheler J, Hess KR, Falchook G, Fu S, Naing A, Hong D, Piha-Paul S, Ye Y, Yeh E, Wolff RA, Tsimberidou AM. The prognostic significance of left ventricular ejection fraction in patients with advanced cancer treated in phase I clinical trials. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 25: 276-82. PMID 24356639 DOI: 10.1093/annonc/mdt524  1
2014 Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, Shonka N, Gilbert MR, Sawaya R, Prabhu SS, Weinberg J, Lang FF, Aldape KD, Sulman EP, Rao G, et al. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. Neuro-Oncology. 16: 81-91. PMID 24305719 DOI: 10.1093/Neuonc/Not159  1
2014 Jardim DL, Hess KR, Lorusso P, Kurzrock R, Hong DS. Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugs. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 281-8. PMID 24190980 DOI: 10.1158/1078-0432.CCR-13-2103  1
2014 Wang-Johanning F, Li M, Esteva FJ, Hess KR, Yin B, Rycaj K, Plummer JB, Garza JG, Ambs S, Johanning GL. Human endogenous retrovirus type K antibodies and mRNA as serum biomarkers of early-stage breast cancer. International Journal of Cancer. Journal International Du Cancer. 134: 587-95. PMID 23873154 DOI: 10.1002/Ijc.28389  1
2014 Falchook GS, Naing A, Wheler JJ, Tsimberidou AM, Zinner R, Hong DS, Fu S, Piha-Paul SA, Janku F, Hess KR, Bastida C, Kurzrock R. Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer Oncoscience. 1: 540-549. DOI: 10.18632/oncoscience.73  1
2014 Tang C, Jardim DLF, Falchook GS, Hess K, Fu S, Wheler JJ, Zinner RG, Naing A, Tsimberidou AM, Galgiato DDM, Westin SN, Meric-Bernstam F, Kurzrock R, Hong DS. MET nucleotide variations and amplification in advanced ovarian cancer: Characteristics and outcomes with c-Met inhibitors Oncoscience. 1: 5-13. DOI: 10.18632/oncoscience.3  1
2014 Hu Y, Gao H, Vo C, Ke C, Pan F, Yu L, Siegel E, Hess KR, Linskey ME, Zhou YH. Anti-EGFR function of EFEMP1 in glioma cells and patient prognosis Oncoscience. 1: 205-215. DOI: 10.18632/oncoscience.24  1
2014 Fontes Jardim DL, Gagliato DDM, Falchook GS, Wheler JJ, Zinner R, Janku F, Subbiah V, Piha-Paul SA, Fu S, Tannir NM, Corn PG, Tang C, Hess KR, Roy-Chowdhuri S, Kurzrock R, et al. c-Met abnormatities in patients with genitourinary (GU) malignancies and outcomes with c-MET inhibitors. Journal of Clinical Oncology. 32: 407-407. DOI: 10.1200/Jco.2014.32.4_Suppl.407  0.01
2014 Dasari A, Phan A, Gupta S, Hess KR, Culotta KS, Rashid A, Yeung SJ, Chen HX, Dong M, Halperin DM, Subbiah IM, Meric-Bernstam F, Yao JC. A phase I study of the anti-IGF-1R monoclonal antibody (MoAb), IMC-A12 (I), and everolimus (E) in well-differentiated neuroendocrine tumors (WD NET). Journal of Clinical Oncology. 32: 232-232. DOI: 10.1200/JCO.2014.32.3_SUPPL.232  0.01
2014 Subbiah V, Corrales-Medina FF, Herzog CE, Hess KR, Egas Bejar DE, Hong DS, Falchook GS, Anderson PM, Nunez C, Huh WW, Naing A, Tsimberidou AM, Wheler JJ, Piha-Paul SA, Janku F, et al. Outcomes of pediatric cancer patients enrolled in phase 1 clinical trials designed for adults: Experience from a major cancer center. Journal of Clinical Oncology. 32: e21024-e21024. DOI: 10.1200/Jco.2014.32.15_Suppl.E21024  0.01
2014 Bilen MA, Hess KR, Aparicio A, Kim J, Zurita AJ, Pagliaro LC, Araujo JC, Corn PG, Atkinson BJ, Tannir NM, Sharma P, Lin S, Logothetis C, Tu S. Sipuleucel-T cellular immunotherapy: Clinical predictors of survival in patients with castration-resistant prostate cancer (CRPC). Journal of Clinical Oncology. 32: e16046-e16046. DOI: 10.1200/JCO.2014.32.15_SUPPL.E16046  0.01
2014 Tsimberidou AM, Ye Y, Wheler JJ, Falchook GS, Hong DS, Naing A, Fu S, Kurzrock R, Piha-Paul SA, Janku F, Zinner R, Moulder SL, Subbiah V, Karp DD, Meric-Bernstam F, ... ... Hess KR, et al. Genomic profiling and precision medicine in 3,745 patients with advanced cancer. Journal of Clinical Oncology. 32: e13521-e13521. DOI: 10.1200/Jco.2014.32.15_Suppl.E13521  0.01
2014 Hou M, Bellido J, Naing A, Falchook GS, Hess KR, Zinner R, Wheler JJ, Subbiah V, Hong DS, Piha-Paul SA, Tsimberidou AM, Karp DD, Kurzrock R, Meric-Bernstam F, Fu S. A phase I trial of pazopanib and vorinostat: The role of TP53 mutations. Journal of Clinical Oncology. 32: 2576-2576. DOI: 10.1200/Jco.2014.32.15_Suppl.2576  0.01
2014 Livingston JA, Hess KR, Fernandez JG, Naing A, Hong DS, Patel S, Anderson PM, Benjamin RS, Ludwig JA, Herzog CE, Fu S, Wheler JJ, Falchook GS, Tsimberidou AM, Piha-Paul SA, et al. Eliciting early-response signals from first-in-human clinical trials and validation of prognostic scores in aggressive biology bone cancers: The MD Anderson experience. Journal of Clinical Oncology. 32: 10531-10531. DOI: 10.1200/Jco.2014.32.15_Suppl.10531  0.01
2014 Hess K. Ritual power: Illuminating the blind spot of births, deaths and marriages in news media research Journalism. 17: 511-526. DOI: 10.1177/1464884915570419  1
2014 Tsimberidou AM, Culotta K, Wistuba I, Fu S, Naing A, Falchook G, Piha-Paul S, Zinner R, Rodriguez-Canales J, He G, Siddik ZH, Jelinek J, Chung W, Ye Y, Said R, ... Hess K, et al. Abstract CT201: Phase I study of 5-azacytidine and oxaliplatin in patients with advanced cancers relapsed or refractory to platinum compounds Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Ct201  1
2014 Tang C, Jardim D, Gagliato D, Falchook G, Hess K, Fu S, Wheler J, Zinner R, Naing A, Tsimberidou A, Meric-Bernstam F, Hong D. Abstract 4424: Analysis of 1115 patients tested for MET amplification and therapy response in the MD Anderson phase I clinic Cancer Research. 74: 4424-4424. DOI: 10.1158/1538-7445.Am2014-4424  1
2014 Hess KM. Because they can: The basis for the moral obligations of (certain) collectives Midwest Studies in Philosophy. 38: 203-221. DOI: 10.1111/misp.12024  1
2014 Kurnatowska I, Grzelak P, Masajtis-Zagajewska A, Kaczmarska M, Stefańczyk L, Vermeer C, Maresz K, Nowicki M, Patel L, Bernard LM, Elder GJ, Leonardis D, Mallamaci F, Tripepi G, D'Arrigo G, ... ... Hess K, et al. Ckd Pathophysiology And Clinical Studies Nephrology Dialysis Transplantation. 29. DOI: 10.1093/Ndt/Gfu148  0.01
2014 Bupathi M, Hajjar J, Hess K, Bean S, Karp D, Meric-Bernstam F, Naing A. 425 Evaluation of drug reactions to anti-neoplastic agents in Phase I clinical trials European Journal of Cancer. 50: 136. DOI: 10.1016/S0959-8049(14)70551-9  1
2014 Bugano D, Hess K, Siu LL, Meric-Bernstam F, Razak ARA, Hong DS. 237 Impact of phase 1 expansion cohorts on probability of success in phase 2 and time-to-drug-approval: analysis of 385 new drugs in oncology European Journal of Cancer. 50: 79-80. DOI: 10.1016/S0959-8049(14)70363-6  1
2014 Shaitelman S, Tereffe W, Hess K, Gonzalez Angulo A, Dogan B, Stauder M, Valero V, Krishnamurthy S, Strom E, Hunt K, Buchholz T, Whitman G. The Role of Ultrasound of the Regional Nodal Basins in Staging Patients With Triple-Negative Breast Cancer: Implications for Local-Regional Treatment International Journal of Radiation Oncology*Biology*Physics. 90: S172. DOI: 10.1016/J.Ijrobp.2014.05.679  0.01
2014 Pan H, Morani A, Wang W, Hess K, Lin P, Daw N, Mahajan A. Utility of Histologic and Radiologic Response to Induction Chemotherapy in Patients With Ewing Sarcoma (EWS) International Journal of Radiation Oncology*Biology*Physics. 90: S116. DOI: 10.1016/j.ijrobp.2014.05.544  0.01
2014 Tang C, Gomez D, Hess K, Zhuang Y, Xu T, Nguyen Q, Komaki R, Liao Z. Predictors of Site-Specific Distant Metastasis After Definitive Radiation Therapy in Non-Small Cell Lung Cancer and the Impact of Metastatic Location on Survival International Journal of Radiation Oncology*Biology*Physics. 90: S616. DOI: 10.1016/j.ijrobp.2014.05.1838  0.01
2014 Hess KM. The free will of corporations (and other collectives) Philosophical Studies. 168: 241-260. DOI: 10.1007/s11098-013-0128-4  1
2014 Hess K. Behavior change is an opportunity that mhealth can address Medical Device and Diagnostic Industry. 36.  1
2013 Zippin JH, Chen Y, Straub SG, Hess KC, Diaz A, Lee D, Tso P, Holz GG, Sharp GW, Levin LR, Buck J. CO2/HCO3(-)- and calcium-regulated soluble adenylyl cyclase as a physiological ATP sensor. The Journal of Biological Chemistry. 288: 33283-91. PMID 24100033 DOI: 10.1074/Jbc.M113.510073  1
2013 Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget. 4: 153-62. PMID 23847722 DOI: 10.18632/oncotarget.832  1
2013 Giordano A, Gao H, Cohen EN, Anfossi S, Khoury J, Hess K, Krishnamurthy S, Tin S, Cristofanilli M, Hortobagyi GN, Woodward WA, Lucci A, Reuben JM. Clinical relevance of cancer stem cells in bone marrow of early breast cancer patients. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 24: 2515-21. PMID 23798614 DOI: 10.1093/annonc/mdt223  1
2013 Yost K, Hess K. The concept of caring Imprint. 60: 44-45. PMID 23617049  1
2013 Liedtke C, Hess KR, Karn T, Rody A, Kiesel L, Hortobagyi GN, Pusztai L, Gonzalez-Angulo AM. The prognostic impact of age in patients with triple-negative breast cancer. Breast Cancer Research and Treatment. 138: 591-9. PMID 23460246 DOI: 10.1007/s10549-013-2461-x  0.01
2013 Wu AS, Trinh VT, Suki D, Graham S, Forman A, Weinberg JS, McCutcheon IE, Prabhu SS, Heimberger AB, Sawaya R, Wang X, Qiao W, Hess KR, Lang FF. A prospective randomized trial of perioperative seizure prophylaxis in patients with intraparenchymal brain tumors. Journal of Neurosurgery. 118: 873-83. PMID 23394340 DOI: 10.3171/2012.12.Jns111970  1
2013 Subbiah IM, Subbiah V, Tsimberidou AM, Naing A, Kaseb AO, Javle M, Fu S, Hong DS, Piha-Paul S, Wheler JJ, Hess KR, Janku F, Falchook GS, Wolff RA, Kurzrock R. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget. 4: 156-65. PMID 23391555 DOI: 10.18632/Oncotarget.832  1
2013 Tsimberidou AM, Ye Y, Wheler J, Naing A, Hong D, Nwosu U, Hess KR, Wolff RA. A phase I study of hepatic arterial infusion of nab-paclitaxel in combination with intravenous gemcitabine and bevacizumab for patients with advanced cancers and predominant liver metastases. Cancer Chemotherapy and Pharmacology. 71: 955-63. PMID 23377373 DOI: 10.1007/s00280-013-2088-y  1
2013 Dean-Colomb W, Hess KR, Young E, Gornet TG, Handy BC, Moulder SL, Ibrahim N, Pusztai L, Booser D, Valero V, Hortobagyi GN, Esteva FJ. Elevated serum P1NP predicts development of bone metastasis and survival in early-stage breast cancer. Breast Cancer Research and Treatment. 137: 631-6. PMID 23242617 DOI: 10.1007/s10549-012-2374-0  1
2013 Hess KR, Esteva FJ. Effect of HER2 status on distant recurrence in early stage breast cancer. Breast Cancer Research and Treatment. 137: 449-55. PMID 23225147 DOI: 10.1007/s10549-012-2366-0  1
2013 González L, Magno P, Ortiz AP, Ortiz-Ortiz K, Hess K, Nogueras-González GM, Suárez E. Esophageal cancer incidence rates by histological type and overall: Puerto Rico versus the United States Surveillance, Epidemiology, and End Results population, 1992-2005. Cancer Epidemiology. 37: 5-10. PMID 23063415 DOI: 10.1016/j.canep.2012.09.002  1
2013 Subbiah IM, Janku F, Tsimberidou AM, Naing A, Kaseb AO, Hong DS, Subbiah V, Hess KR, Akmal O, Falchook GS, Kurzrock R. Characteristics and outcomes of patients with advanced hepatocellular carcinoma treated on phase I trials. Journal of Clinical Oncology. 31: 281-281. DOI: 10.1200/Jco.2013.31.4_Suppl.281  0.01
2013 Penas-Prado M, Groves MD, Mammoser AG, Melguizo I, De Groot JF, Conrad CA, Tremont-Lukats I, Loghin ME, Puduvalli VK, Sulman EP, Hess KR, Aldape KD, Gilbert MR, Yung WKA. Phase I lead-in to a 2x2x2 factorial trial of dose-dense temozolomide, memantine, mefloquine, and metformin as postradiation adjuvant therapy of glioblastoma (GBM). Journal of Clinical Oncology. 31: TPS2106-TPS2106. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps2106  0.01
2013 Subbiah IM, Wheler JJ, Hess KR, Hong DS, Fu S, Wolff RA, Kurzrock R, Tsimberidou AM. Outcomes of patients ≥ 65 yrs with advanced cancer treated on phase I clinical trials. Journal of Clinical Oncology. 31: 9544-9544. DOI: 10.1200/Jco.2013.31.15_Suppl.9544  0.01
2013 Said R, Ye Y, Hong DS, Janku F, Fu S, Naing A, Wheler JJ, Kurzrock R, Thomas C, Palmer GA, Hess KR, Wolff RA, Tsimberidou AM. Characteristics and survival of patients with advanced cancer and TP53 mutations in phase I clinical trials. Journal of Clinical Oncology. 31: 2545-2545. DOI: 10.1200/Jco.2013.31.15_Suppl.2545  0.01
2013 Fontes Jardim DL, Hess KR, LoRusso P, Kurzrock R, Hong DS. Predictive value of phase I trials for safety and final approved dose in later trials: Analysis of 33,845 patients. Journal of Clinical Oncology. 31: 2509-2509. DOI: 10.1200/Jco.2013.31.15_Suppl.2509  0.01
2013 Abdelrahim M, Naing A, Dalal S, Wheler J, Hess K, Fu S, Hong DS, Janku F, Falchook GS, Ilustre A, Ouyang F, Kurzrock R. Abstract B82: Olanzapine for cachexia in patients with advanced cancer. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B82  1
2013 Hess KP. Investigation of nonverbal discrimination against women in simulated initial job interviews Journal of Applied Social Psychology. 43: 544-555. DOI: 10.1111/j.1559-1816.2013.01034.x  1
2013 Hess K. Tertius Tactics: "Mediated Social Capital" as a Resource of Power for Traditional Commercial News Media Communication Theory. 23: 112-130. DOI: 10.1111/comt.12005  1
2013 Agarwal M, Nitta R, Dovat S, Li G, Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP, Kawahara N, Shibui S, ... ... Hess KR, et al. CELL BIOLOGY AND SIGNALING Neuro-Oncology. 15: iii12-iii31. DOI: 10.1093/Neuonc/Not174  0.01
2013 Hess K. Breaking boundaries: Recasting the ʺlocalʺ newspaper as ʺgeo-socialʺ news in a digital landscape Digital Journalism. 1: 48-63. DOI: 10.1080/00167223.2012.714933  1
2013 Hess KM. "If You Tickle Us....": How Corporations Can Be Moral Agents Without Being Persons Journal of Value Inquiry. 47: 319-335. DOI: 10.1007/s10790-013-9391-z  1
2013 Hess K. Journey to incident-free workplace Aiche Annual Meeting, Conference Proceedings 1
2012 Hess KR, Young EJ, Gornet T, Handy BC, Moulder SL, Ibrahim NK, Pusztai L, Booser DJ, Valero V, Hortobagyi GN, Esteva FJ. Evaluation of circulating biomarkers of bone metastases in early-stage breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 10. PMID 28142474 DOI: 10.1200/jco.2012.30.30_suppl.10  1
2012 Delpech Y, Wu Y, Hess KR, Hsu L, Ayers M, Natowicz R, Coutant C, Rouzier R, Barranger E, Hortobagyi GN, Mauro D, Pusztai L. Ki67 expression in the primary tumor predicts for clinical benefit and time to progression on first-line endocrine therapy in estrogen receptor-positive metastatic breast cancer. Breast Cancer Research and Treatment. 135: 619-27. PMID 22890751 DOI: 10.1007/s10549-012-2194-2  0.01
2012 Salazar E, Bank EM, Ramsey N, Hess KC, Deitsch KW, Levin LR, Buck J. Characterization of Plasmodium falciparum adenylyl cyclase-β and its role in erythrocytic stage parasites. Plos One. 7: e39769. PMID 22761895 DOI: 10.1371/Journal.Pone.0039769  1
2012 Suárez E, González L, Soto-Salgado M, Bayona M, Hess K, Ortiz AP, Pérez CM. Report of the 2011 University of Puerto Rico-MD Anderson Cancer Center conference entitled "Population-Based Studies in Hispanics: Methodological Issues in Cancer Research". Puerto Rico Health Sciences Journal. 31: 39-41. PMID 22432409  1
2012 Lang FF, Sawaya R, Suki D, McCutcheon IE, Hess KR. Glioblastoma resection. Journal of Neurosurgery. 116: 1166-7; author reply. PMID 22385007 DOI: 10.3171/2011.8.Jns11637C  0.01
2012 Holmes KM, Annala M, Chua CY, Dunlap SM, Liu Y, Hugen N, Moore LM, Cogdell D, Hu L, Nykter M, Hess K, Fuller GN, Zhang W. Insulin-like growth factor-binding protein 2-driven glioma progression is prevented by blocking a clinically significant integrin, integrin-linked kinase, and NF-κB network. Proceedings of the National Academy of Sciences of the United States of America. 109: 3475-80. PMID 22345562 DOI: 10.1073/pnas.1120375109  1
2012 Hightower E, Cabanillas ME, Fuller GN, McCutcheon IE, Hess KR, Shah K, Waguespack SG, Corley LJ, Devin JK. Phospho-histone H3 (pHH3) immuno-reactivity as a prognostic marker in non-functioning pituitary adenomas. Pituitary. 15: 556-61. PMID 22120760 DOI: 10.1007/s11102-011-0367-3  1
2012 Giglio P, Dhamne M, Hess KR, Gilbert MR, Groves MD, Levin VA, Kang SL, Ictech SE, Liu V, Colman H, Conrad CA, Loghin M, de Groot J, Yung WK, Puduvalli VK. Phase 2 trial of irinotecan and thalidomide in adults with recurrent anaplastic glioma. Cancer. 118: 3599-606. PMID 22086614 DOI: 10.1002/Cncr.26663  1
2012 Liedtke C, Packeisen J, Hess KR, Vogt U, Kiesel L, Kersting C, Korsching E, Brandt B, Buerger H. Systematic analysis of in vitro chemosensitivity and mib-1 expression in molecular breast cancer subtypes. European Journal of Cancer (Oxford, England : 1990). 48: 2066-74. PMID 21920731 DOI: 10.1016/j.ejca.2011.08.006  1
2012 Dong X, Li Y, Tang H, Chang P, Hess KR, Abbruzzese JL, Li D. Insulin-like growth factor axis gene polymorphisms modify risk of pancreatic cancer. Cancer Epidemiology. 36: 206-11. PMID 21852217 DOI: 10.1016/J.Canep.2011.05.013  1
2012 Dong X, Li Y, Chang P, Hess KR, Abbruzzese JL, Li D. DNA mismatch repair network gene polymorphism as a susceptibility factor for pancreatic cancer. Molecular Carcinogenesis. 51: 491-9. PMID 21681824 DOI: 10.1002/Mc.20817  1
2012 Hess K, Waller L. 'The Snowtown we know and love': Small newspapers and heinous crimes Rural Society. 21: 116-125. DOI: 10.5172/rsj.2012.21.2.116  1
2012 Subbiah IM, Tsimberidou AM, Naing A, Subbiah V, Kaseb AO, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Janku F, Hess KR, Falchook GS, Kurzrock R. Early-phase trials compared to first- and second-line FDA-approved treatments in patients with advanced gallbladder cancer and cholangiocarcinoma. Journal of Clinical Oncology. 30. DOI: 10.1200/Jco.2012.30.15_Suppl.E13020  1
2012 Barcenas CH, Hess KR, Delpech Y, Pusztai L, Hortobagyi GN, Giordano SH, Esteva FJ. Survival outcomes in HER2-positive invasive lobular breast carcinoma. Journal of Clinical Oncology. 30: 612-612. DOI: 10.1200/JCO.2012.30.15_SUPPL.612  0.01
2012 Murthy RK, Varma A, Mishra P, Hess KR, Young EJ, Murray JL, Koenig KH, Green MC, Moulder SL, Melhem-Bertrandt A, Booser DJ, Valero V, Hortobagyi GN, Esteva FJ. Impact of adjuvant trastuzumab on outcomes of HER2-positive breast cancer patients treated with HER2-targeted therapy in the metastatic setting. Journal of Clinical Oncology. 30: 527-527. DOI: 10.1200/JCO.2012.30.15_SUPPL.527  0.01
2012 Puduvalli VK, Groves MD, Gilbert MR, Hess KR, Kang S, Ictech S, Conrad CA, Loghin ME, De Groot JF, Levin VA, Yung WKA. Lenalidomide and irinotecan in adults with recurrent malignant gliomas: Phase I results of the phase I/II trial. Journal of Clinical Oncology. 30: 2036-2036. DOI: 10.1200/Jco.2012.30.15_Suppl.2036  0.01
2012 Wu J, Groves MD, Gilbert MR, Hess KR, Loch CS, Ictech S, De Groot JF, Conrad CA, Yung WKA, Puduvalli VK. Bevacizumab versus bevacizumab plus vorinostat in adults with recurrent malignant glioma: Results of a phase I part of a phase I/II trial. Journal of Clinical Oncology. 30: 2029-2029. DOI: 10.1200/Jco.2012.30.15_Suppl.2029  0.01
2012 Gilbert MR, Hess KR, Lagrone L, Groves MD, Levin VA, Groot JFD, Loghin ME, Puduvalli VK, Fisch M, Giglio P, Colman H, Conrad CA, Aldape KD, Yung WKA. Randomized phase II 8-arm factorial study of adjuvant dose-dense (dd) temozolomide (TMZ) with permutations of thalidomide (Thal), isotretinoin (CRA), and/or celecoxib (Cel) for newly diagnosed glioblastoma (GBM). Journal of Clinical Oncology. 30: 2003-2003. DOI: 10.1200/Jco.2012.30.15_Suppl.2003  1
2012 Liedtke C, Packeisen J, Denkert C, Kiesel L, Vogt U, Mueller B, Hess KR, Buerger H. Correlation between in vitro chemotherapy sensitivity and PARP-1 expression in patients with breast cancer. Journal of Clinical Oncology. 30: 10627-10627. DOI: 10.1200/JCO.2012.30.15_SUPPL.10627  0.01
2012 Yang D, Khan S, Sun Y, Hess KR, Shmulevich I, Sood AK, Zhang W. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer Obstetrical & Gynecological Survey. 67: 164-165. DOI: 10.1097/Ogx.0B013E31824B70B7  1
2012 Park C-, Kim Y-, Kim JW, Kim TM, Choi SH, Kim YJ, Choi BS, Lee S-, Kim C-, Kim IH, Lee DZ, Kheder A, Forbes M, Craven I, Hadjivassiliou M, ... ... Hess KR, et al. Clin-Neuro/Medical Oncology Neuro-Oncology. 14. DOI: 10.1093/Neuonc/Nos229  1
2012 Chouchane L, Shan S, al-Rumaihi K, al-Bozom I, al-Said S, Rabah D, Farhat K, Kizhakayil D, Aigha I. P1.08 Identification of Three Genomic Regions with Multiple Consecutive Prostate Cancer Susceptibility Loci Through a Genome-Wide Association Study in ARAB Population Annals of Oncology. 23: v14. DOI: 10.1016/s0923-7534(20)31299-0  0.01
2012 Hess K. Multiplicative structure in equivariant cohomology Journal of Pure and Applied Algebra. 216: 1680-1699. DOI: 10.1016/j.jpaa.2011.12.012  1
2012 Xiang Z, Hess K, Zhang X, Liang S, Chang J. A Dosimetric Model for Predicting Radiation Pneumonitis After Stereotactic Ablative Radiation Therapy for Stage I Non-small Cell Lung Cancer International Journal of Radiation Oncology*Biology*Physics. 84: S557. DOI: 10.1016/J.IJROBP.2012.07.1484  0.01
2012 Hess KT. Maximum-likelihood and marginal-sum estimation in some particular collective models Asta Advances in Statistical Analysis. 96: 311-326. DOI: 10.1007/s10182-011-0178-x  1
2011 Hess KR, Wei C, Qi Y, Iwamoto T, Symmans WF, Pusztai L. Lack of sufficiently strong informative features limits the potential of gene expression analysis as predictive tool for many clinical classification problems. Bmc Bioinformatics. 12: 463. PMID 22132775 DOI: 10.1186/1471-2105-12-463  1
2011 Lee YS, Tresguerres M, Hess K, Marmorstein LY, Levin LR, Buck J, Marmorstein AD. Regulation of anterior chamber drainage by bicarbonate-sensitive soluble adenylyl cyclase in the ciliary body. The Journal of Biological Chemistry. 286: 41353-8. PMID 21994938 DOI: 10.1074/Jbc.M111.284679  1
2011 Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood AK, Zhang W. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. Jama. 306: 1557-65. PMID 21990299 DOI: 10.1001/Jama.2011.1456  1
2011 Hu Y, Pioli PD, Siegel E, Zhang Q, Nelson J, Chaturbedi A, Mathews MS, Ro DI, Alkafeef S, Hsu N, Hamamura M, Yu L, Hess KR, Tromberg BJ, Linskey ME, et al. EFEMP1 suppresses malignant glioma growth and exerts its action within the tumor extracellular compartment. Molecular Cancer. 10: 123. PMID 21955618 DOI: 10.1186/1476-4598-10-123  1
2011 Giordano A, Giuliano M, De Laurentiis M, Eleuteri A, Iorio F, Tagliaferri R, Hortobagyi GN, Pusztai L, De Placido S, Hess K, Cristofanilli M, Reuben JM. Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. Breast Cancer Research and Treatment. 129: 451-8. PMID 21710134 DOI: 10.1007/S10549-011-1645-5  1
2011 Giuliano M, Giordano A, Jackson S, Hess KR, De Giorgi U, Mego M, Handy BC, Ueno NT, Alvarez RH, De Laurentiis M, De Placido S, Valero V, Hortobagyi GN, Reuben JM, Cristofanilli M. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Research : Bcr. 13: R67. PMID 21699723 DOI: 10.1186/bcr2907  1
2011 Ramos-Espiritu LS, Hess KC, Buck J, Levin LR. The soluble guanylyl cyclase activator YC-1 increases intracellular cGMP and cAMP via independent mechanisms in INS-1E cells. The Journal of Pharmacology and Experimental Therapeutics. 338: 925-31. PMID 21665942 DOI: 10.1124/Jpet.111.184135  1
2011 Hess KL, Corda CJ, Lanese KM. SPORE series winner. Science Buddies: advancing informal science education. Science (New York, N.Y.). 332: 550-1. PMID 21527706 DOI: 10.1126/science.1196978  1
2011 Dong X, Li Y, Chang P, Tang H, Hess KR, Abbruzzese JL, Li D. Glucose metabolism gene variants modulate the risk of pancreatic cancer. Cancer Prevention Research (Philadelphia, Pa.). 4: 758-66. PMID 21411499 DOI: 10.1158/1940-6207.Capr-10-0247  1
2011 Kelly CM, Pritchard KI, Trudeau M, Andreopoulou E, Hess K, Pusztai L. Coping with uncertainty: T1a,bN0M0 HER2-positive breast cancer, do we have a treatment threshold? Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 22: 2387-93. PMID 21406473 DOI: 10.1093/Annonc/Mdq786  1
2011 Hess KR. Statistical design considerations in animal studies published recently in cancer research. Cancer Research. 71: 625. PMID 21239476 DOI: 10.1158/0008-5472.CAN-10-3296  1
2011 Dong X, Li Y, Hess KR, Abbruzzese JL, Li D. DNA mismatch repair gene polymorphisms affect survival in pancreatic cancer. The Oncologist. 16: 61-70. PMID 21212431 DOI: 10.1634/Theoncologist.2010-0127  1
2011 Dong X, Tang H, Hess KR, Abbruzzese JL, Li D. Glucose metabolism gene polymorphisms and clinical outcome in pancreatic cancer. Cancer. 117: 480-91. PMID 20845477 DOI: 10.1002/Cncr.25612  1
2011 El-Rayes BF, Philip PA, Sarkar FH, Shields AF, Ferris AM, Hess K, Kaseb AO, Javle MM, Varadhachary GR, Wolff RA, Abbruzzese JL. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Investigational New Drugs. 29: 694-9. PMID 20107864 DOI: 10.1007/S10637-010-9386-6  1
2011 Melguizo I, Hess KR, Blas-Boria D, Bruner J, Guha-Thakurta N, Puduvalli VK. The effect of surgery in determining pseudoprogression and predicting outcome in adults with glioblastoma. Journal of Clinical Oncology. 29: 2067-2067. DOI: 10.1200/jco.2011.29.15_suppl.2067  0.01
2011 Hess K. Nano-structures, quantum computing and cellular automata Journal of Computational and Theoretical Nanoscience. 8: 949-952. DOI: 10.1166/Jctn.2011.1774  1
2011 Moriera F, So K, Gould P, Kamnasaran D, Jensen RL, Hussain I, Gutmann DH, Gorovets D, Kastenhuber ER, Pentsova E, Nayak L, Huse JT, van den Bent MJ, Gravendeel LA, Gorlia T, et al. -OMICS AND PROGNOSTIC MARKERS Neuro-Oncology. 13: iii76-iii84. DOI: 10.1093/Neuonc/Nor167  0.01
2011 Prithviraj GK, Sommers SR, Jump RL, Halmos B, Chambless LB, Parker SL, Hassam-Malani L, McGirt MJ, Thompson RC, Chambless LB, Parker SL, Hassam-Malani L, McGirt MJ, Thompson RC, Hunter K, ... ... Hess K, ... ... Hess KR, et al. MEDICAL AND NEURO-ONCOLOGY Neuro-Oncology. 13: iii41-iii68. DOI: 10.1093/Neuonc/Nor152  0.01
2011 Hess KM. Shifting the burden Ethics, Policy and Environment. 14: 159-162. DOI: 10.1080/21550085.2011.578374  1
2011 Hess K. It's time for more focus on educator involvement in developing and using learning progressions Measurement. 9: 152-154. DOI: 10.1080/15366367.2011.605039  1
2011 Liedtke C, Packeisen J, Denkert C, Gluz O, Tio J, Kiesel L, Vogt U, Müller B, Hess K, Bürger H. 5177 POSTER Correlation Between PARP-1 Expression and ln-vitro Chemotherapy Sensitivity in Patients With Breast Cancer European Journal of Cancer. 47: S383. DOI: 10.1016/S0959-8049(11)71619-7  0.01
2010 Zhou YH, Hess KR, Raj VR, Yu L, Liu L, Yung AW, Linskey ME. Establishment of prognostic models for astrocytic and oligodendroglial brain tumors with standardized quantification of marker gene expression and clinical variables. Biomarker Insights. 5: 153-68. PMID 21234290 DOI: 10.4137/BMI.S6167  1
2010 Peeler JC, Woodman BF, Averick S, Miyake-Stoner SJ, Stokes AL, Hess KR, Matyjaszewski K, Mehl RA. Genetically encoded initiator for polymer growth from proteins. Journal of the American Chemical Society. 132: 13575-7. PMID 20839808 DOI: 10.1021/ja104493d  1
2010 Tabchy A, Valero V, Vidaurre T, Lluch A, Gomez H, Martin M, Qi Y, Barajas-Figueroa LJ, Souchon E, Coutant C, Doimi FD, Ibrahim NK, Gong Y, Hortobagyi GN, Hess KR, et al. Evaluation of a 30-gene paclitaxel, fluorouracil, doxorubicin, and cyclophosphamide chemotherapy response predictor in a multicenter randomized trial in breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 5351-61. PMID 20829329 DOI: 10.1158/1078-0432.CCR-10-1265  1
2010 Hess KR. Comparing survival curves using an easy to interpret statistic. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 4912-3. PMID 20732962 DOI: 10.1158/1078-0432.CCR-10-1540  1
2010 Gilbert MR, Gonzalez J, Hunter K, Hess K, Giglio P, Chang E, Puduvalli V, Groves MD, Colman H, Conrad C, Levin V, Woo S, Mahajan A, de Groot J, Yung WK. A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, isotretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. Neuro-Oncology. 12: 1167-72. PMID 20729242 DOI: 10.1093/Neuonc/Noq100  1
2010 Shi L, Campbell G, Jones WD, Campagne F, Wen Z, Walker SJ, Su Z, Chu TM, Goodsaid FM, Pusztai L, Shaughnessy JD, Oberthuer A, Thomas RS, Paules RS, Fielden M, ... ... Hess KR, et al. The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. Nature Biotechnology. 28: 827-38. PMID 20676074 DOI: 10.1038/Nbt.1665  1
2010 Moulder S, Yan K, Huang F, Hess KR, Liedtke C, Lin F, Hatzis C, Hortobagyi GN, Symmans WF, Pusztai L. Development of candidate genomic markers to select breast cancer patients for dasatinib therapy. Molecular Cancer Therapeutics. 9: 1120-7. PMID 20423993 DOI: 10.1158/1535-7163.MCT-09-1117  1
2010 Dong X, Javle M, Hess KR, Shroff R, Abbruzzese JL, Li D. Insulin-like growth factor axis gene polymorphisms and clinical outcomes in pancreatic cancer. Gastroenterology. 139: 464-73, 473.e1-3. PMID 20416304 DOI: 10.1053/J.Gastro.2010.04.042  1
2010 Hess KR, Wei C. Learning curves in classification with microarray data. Seminars in Oncology. 37: 65-8. PMID 20172367 DOI: 10.1053/j.seminoncol.2009.12.002  1
2010 Popovici V, Chen W, Gallas BG, Hatzis C, Shi W, Samuelson FW, Nikolsky Y, Tsyganova M, Ishkin A, Nikolskaya T, Hess KR, Valero V, Booser D, Delorenzi M, Hortobagyi GN, et al. Effect of training-sample size and classification difficulty on the accuracy of genomic predictors. Breast Cancer Research : Bcr. 12: R5. PMID 20064235 DOI: 10.1186/Bcr2468  1
2010 Liedtke C, Wang J, Tordai A, Symmans WF, Hortobagyi GN, Kiesel L, Hess K, Baggerly KA, Coombes KR, Pusztai L. Clinical evaluation of chemotherapy response predictors developed from breast cancer cell lines. Breast Cancer Research and Treatment. 121: 301-9. PMID 19603265 DOI: 10.1007/s10549-009-0445-7  1
2010 Yang WT, Lewis MT, Hess K, Wong H, Tsimelzon A, Karadag N, Cairo M, Wei C, Meric-Bernstam F, Brown P, Arun B, Hortobagyi GN, Sahin A, Chang JC. Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Research and Treatment. 119: 305-14. PMID 19241157 DOI: 10.1007/s10549-009-0350-0  1
2010 Yao JC, Phan AT, Fogleman D, Ng CS, Jacobs CB, Dagohoy CD, Leary C, Hess KR. Randomized run-in study of bevacizumab (B) and everolimus (E) in low- to intermediate-grade neuroendocrine tumors (LGNETs) using perfusion CT as functional biomarker. Journal of Clinical Oncology. 28: 4002-4002. DOI: 10.1200/JCO.2010.28.15_SUPPL.4002  0.01
2010 Phan AT, Yao JC, Fogelman DR, Hess KR, Ng CS, Bullock SA, Malinowski P, Regan E, Kulke M. A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC). Journal of Clinical Oncology. 28: 4001-4001. DOI: 10.1200/JCO.2010.28.15_SUPPL.4001  0.01
2010 Dong X, Tang H, Hess KR, Abbruzzese JL, Li D. Abstract 898: Glucose metabolism Gene Polymorphisms and Clinical Outcome in Pancreatic Cancer Cancer Research. 70: 898-898. DOI: 10.1158/1538-7445.Am10-898  1
2010 Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA. Whole-brain irradiation for patients with brain metastases: still the standard of care - Authors' reply The Lancet Oncology. 11: 223. DOI: 10.1016/S1470-2045(10)70011-5  1
2009 Dupart JJ, Trent JC, Lee HY, Hess KR, Godwin AK, Taguchi T, Zhang W. Insulin-like growth factor binding protein-3 has dual effects on gastrointestinal stromal tumor cell viability and sensitivity to the anti-tumor effects of imatinib mesylate in vitro. Molecular Cancer. 8: 99. PMID 19903356 DOI: 10.1186/1476-4598-8-99  1
2009 Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. The Lancet. Oncology. 10: 1037-44. PMID 19801201 DOI: 10.1016/S1470-2045(09)70263-3  1
2009 Groves MD, Puduvalli VK, Gilbert MR, Levin VA, Conrad CA, Liu VH, Hunter K, Meyers C, Hess KR, Alfred Yung WK. Two phase II trials of temozolomide with interferon-α2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme British Journal of Cancer. 101: 615-620. PMID 19672263 DOI: 10.1038/Sj.Bjc.6605189  1
2009 Miyake-Stoner SJ, Miller AM, Hammill JT, Peeler JC, Hess KR, Mehl RA, Brewer SH. Probing protein folding using site-specifically encoded unnatural amino acids as FRET donors with tryptophan. Biochemistry. 48: 5953-62. PMID 19492814 DOI: 10.1021/Bi900426D  1
2009 Groves MD, Hess KR, Puduvalli VK, Colman H, Conrad CA, Gilbert MR, Weinberg J, Cristofanilli M, Yung WK, Liu TJ. Biomarkers of disease: cerebrospinal fluid vascular endothelial growth factor (VEGF) and stromal cell derived factor (SDF)-1 levels in patients with neoplastic meningitis (NM) due to breast cancer, lung cancer and melanoma. Journal of Neuro-Oncology. 94: 229-34. PMID 19267183 DOI: 10.1007/S11060-009-9819-2  1
2009 Dong X, Jiao L, Li Y, Evans DB, Wang H, Hess KR, Abbruzzese JL, Li D. Significant associations of mismatch repair gene polymorphisms with clinical outcome of pancreatic cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 1592-9. PMID 19237629 DOI: 10.1200/Jco.2008.20.1111  1
2009 Townsend PD, Holliday PM, Fenyk S, Hess KC, Gray MA, Hodgson DR, Cann MJ. Stimulation of mammalian G-protein-responsive adenylyl cyclases by carbon dioxide. The Journal of Biological Chemistry. 284: 784-91. PMID 19008230 DOI: 10.1074/jbc.M807239200  0.01
2009 Tabchy A, Symmans W, Valero V, Vidaurre T, Lluch A, Qi Y, Souchon E, Barajas-Figueroa L, Gomez H, Martin M, Coutant C, Hess K, Hortobagyi G, Pusztai L. Evaluation of the Predictive Performance and Regimen Specificity of a 30-Gene Predictor of Pathologic Complete Response in a Prospective Randomized Neoadjuvant Clinical Trial for Stage I-III Breast Cancer. Cancer Research. 69: 101-101. DOI: 10.1158/0008-5472.Sabcs-09-101  1
2009 Hess KT. Marginal-sum and maximum-likelihood estimation in a multiplicative tariff Asta Advances in Statistical Analysis. 93: 221-233. DOI: 10.1007/s10182-008-0079-9  1
2009 Gabrielian C, Hess K. Pharmacists' role in influenza education and vaccination Pharmacy Times. 75.  1
2008 Yang W, Sahin AA, Wong H, Tsimelzon A, Hess K, Karadag N, Cairo M, Meric F, Arun B, Chang JC. Molecular portraits of mammographic breast density in normal breast tissue. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 22227. PMID 27950301 DOI: 10.1200/Jco.2008.26.15_Suppl.22227  1
2008 Varadhachary GR, Talantov D, Raber MN, Meng C, Hess KR, Jatkoe T, Lenzi R, Spigel DR, Wang Y, Greco FA, Abbruzzese JL, Hainsworth JD. Molecular profiling of carcinoma of unknown primary and correlation with clinical evaluation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4442-8. PMID 18802157 DOI: 10.1200/JCO.2007.14.4378  1
2008 Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, Meric-Bernstam F. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4311-8. PMID 18779618 DOI: 10.1200/JCO.2008.16.7858  1
2008 Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA. Phase 2 trial of oxaliplatin plus capecitabine (XELOX) as second-line therapy for patients with advanced pancreatic cancer. Cancer. 113: 2046-52. PMID 18756532 DOI: 10.1002/cncr.23810  1
2008 Harstad L, Hess KR, Groves MD. Prognostic factors and outcomes in patients with leptomeningeal melanomatosis. Neuro-Oncology. 10: 1010-8. PMID 18708343 DOI: 10.1215/15228517-2008-062  0.01
2008 Pusztai L, Broglio K, Andre F, Symmans WF, Hess KR, Hortobagyi GN. Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 4679-83. PMID 18662965 DOI: 10.1200/JCO.2008.17.2544  0.01
2008 de Groot JF, Gilbert MR, Aldape K, Hess KR, Hanna TA, Ictech S, Groves MD, Conrad C, Colman H, Puduvalli VK, Levin V, Yung WK. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. Journal of Neuro-Oncology. 90: 89-97. PMID 18581057 DOI: 10.1007/S11060-008-9637-Y  1
2008 Yokoyama T, Iwado E, Kondo Y, Aoki H, Hayashi Y, Georgescu MM, Sawaya R, Hess KR, Mills GB, Kawamura H, Hashimoto Y, Urata Y, Fujiwara T, Kondo S. Autophagy-inducing agents augment the antitumor effect of telerase-selve oncolytic adenovirus OBP-405 on glioblastoma cells. Gene Therapy. 15: 1233-9. PMID 18580968 DOI: 10.1038/Gt.2008.98  1
2008 Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 1316-23. PMID 18323556 DOI: 10.1200/JCO.2007.13.6374  1
2008 Groves MD, Glantz MJ, Chamberlain MC, Baumgartner KE, Conrad CA, Hsu S, Wefel JS, Gilbert MR, Ictech S, Hunter KU, Forman AD, Puduvalli VK, Colman H, Hess KR, Yung WK. A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro-Oncology. 10: 208-15. PMID 18316473 DOI: 10.1215/15228517-2007-059  1
2008 Puduvalli VK, Giglio P, Groves MD, Hess KR, Gilbert MR, Mahankali S, Jackson EF, Levin VA, Conrad CA, Hsu SH, Colman H, de Groot JF, Ritterhouse MG, Ictech SE, Yung WK. Phase II trial of irinotecan and thalidomide in adults with recurrent glioblastoma multiforme. Neuro-Oncology. 10: 216-22. PMID 18314417 DOI: 10.1215/15228517-2007-060  1
2008 Aoki H, Kondo Y, Aldape K, Yamamoto A, Iwado E, Yokoyama T, Hollingsworth EF, Kobayashi R, Hess K, Shinojima N, Shingu T, Tamada Y, Zhang L, Conrad C, Bogler O, et al. Monitoring autophagy in glioblastoma with antibody against isoform B of human microtubule-associated protein 1 light chain 3. Autophagy. 4: 467-75. PMID 18259115 DOI: 10.4161/Auto.5668  1
2008 Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 1275-81. PMID 18250347 DOI: 10.1200/JCO.2007.14.4147  0.01
2008 Patel PR, Yao JC, Hess K, Schnirer I, Rashid A, Ajani JA. Effect of timing of metastasis/disease recurrence and histologic differentiation on survival of patients with advanced gastric cancer. Cancer. 110: 2186-90. PMID 17896785 DOI: 10.1002/cncr.23046  0.01
2008 Hess K. Modeling experiments using quantum and Kolmogorov probability Journal of Physics Condensed Matter. 20. DOI: 10.1088/0953-8984/20/45/454207  1
2008 Hess K. History of the Zurich Neurological Clinic and Policlinic Schweizer Archiv Fur Neurologie Und Psychiatrie. 159: 191-197.  1
2007 Kuhn JG, Chang SM, Wen PY, Cloughesy TF, Greenberg H, Schiff D, Conrad C, Fink KL, Robins HI, Mehta M, DeAngelis L, Raizer J, Hess K, Lamborn KR, Dancey J, et al. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 7401-6. PMID 18094423 DOI: 10.1158/1078-0432.CCR-07-0781  1
2007 Aoki H, Yokoyama T, Fujiwara K, Tari AM, Sawaya R, Suki D, Hess KR, Aldape KD, Kondo S, Kumar R, Kondo Y. Phosphorylated Pak1 level in the cytoplasm correlates with shorter survival time in patients with glioblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 6603-9. PMID 18006760 DOI: 10.1158/1078-0432.Ccr-07-0145  1
2007 Pusztai L, Anderson K, Hess KR. Pharmacogenomic predictor discovery in phase II clinical trials for breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 6080-6. PMID 17947471 DOI: 10.1158/1078-0432.CCR-07-0809  0.01
2007 Faria SC, Ng CS, Hess KR, Phongkitkarun S, Szejnfeld J, Daliani D, Charnsangavej C. CT quantification of effects of thalidomide in patients with metastatic renal cell carcinoma. Ajr. American Journal of Roentgenology. 189: 378-85. PMID 17646464 DOI: 10.2214/AJR.07.2164  1
2007 Jiang R, Choi W, Khan A, Hess K, Gerner EW, Casero RA, Yung WK, Hamilton SR, Zhang W. Activation of polyamine catabolism by N1,N11-diethylnorspermine leads to cell death in glioblastoma. International Journal of Oncology. 31: 431-40. PMID 17611701  1
2007 Levin VA, Ictech S, Hess KR. Impact of phase II trials with progression-free survival as end-points on survival-based phase III studies in patients with anaplastic gliomas. Bmc Cancer. 7: 106. PMID 17587447 DOI: 10.1186/1471-2407-7-106  0.01
2007 Aoki H, Iwado E, Eller MS, Kondo Y, Fujiwara K, Li GZ, Hess KR, Siwak DR, Sawaya R, Mills GB, Gilchrest BA, Kondo S. Telomere 3′ overhang-specific DNA oligonucleotides induce autophagy in malignant glioma cells Faseb Journal. 21: 2918-2930. PMID 17449721 DOI: 10.1096/fj.06-6941com  1
2007 Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA, Valero V, Booser D, Pippen JE, Vukelja S, Gomez H, Mejia J, Barajas LJ, Hess KR, et al. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. The Lancet. Oncology. 8: 203-11. PMID 17329190 DOI: 10.1016/S1470-2045(07)70042-6  0.01
2007 Mazouni C, Kau SW, Frye D, Andre F, Kuerer HM, Buchholz TA, Symmans WF, Anderson K, Hess KR, Gonzalez-Angulo AM, Hortobagyi GN, Buzdar AU, Pusztai L. Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 18: 874-80. PMID 17293601 DOI: 10.1093/annonc/mdm008  1
2007 Yao JC, Zhang JX, Rashid A, Yeung SC, Szklaruk J, Hess K, Xie K, Ellis L, Abbruzzese JL, Ajani JA. Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 234-40. PMID 17200360 DOI: 10.1158/1078-0432.Ccr-06-1618  1
2007 Hess KR. Statistical issues in clinical trial design Current Oncology Reports. 9: 55-59. PMID 17164048 DOI: 10.1007/BF02951426  1
2007 Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, DeAngelis LM, Hess KR, et al. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. Journal of Neuro-Oncology. 81: 271-7. PMID 17031561 DOI: 10.1007/S11060-006-9225-Y  1
2007 Hess K, Levi R. An algebraic model for the loop space homology of a homotopy fiber Algebraic and Geometric Topology. 7: 1699-1765. DOI: 10.2140/agt.2007.7.1699  1
2007 Groot JFD, Gilbert MR, Hess KR, Hanna T, Groves M, Conrad C, Aldape K, Colman H, Puduvalli V, Yung WA. Phase II study of combination carboplatin and erlotinib in patients with recurrent glioblastoma multiforme Journal of Clinical Oncology. 25: 2024-2024. DOI: 10.1200/Jco.2007.25.18_Suppl.2024  0.01
2007 Liedtke C, Mazouni C, Hess KR, Tordai A, André F, Symmans WF, Gonzalez-Angulo AM, Green M, Hortobagyi GN, Pusztai L. Differential response to primary chemotherapy and long-term survival in patients with triple-negative breast cancer Journal of Clinical Oncology. 25: 10519-10519. DOI: 10.1200/JCO.2007.25.18_SUPPL.10519  0.01
2006 Rohatgi PR, Yao JC, Hess K, Schnirer I, Rashid A, Mansfield PF, Pisters PW, Ajani JA. Outcome of gastric cancer patients after successful gastrectomy: influence of the type of recurrence and histology on survival. Cancer. 107: 2576-80. PMID 17075877 DOI: 10.1002/cncr.22317  1
2006 Iwamaru A, Szymanski S, Iwado E, Aoki H, Yokoyama T, Fokt I, Hess K, Conrad C, Madden T, Sawaya R, Kondo S, Priebe W, Kondo Y. A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo. Oncogene. 26: 2435-44. PMID 17043651 DOI: 10.1038/Sj.Onc.1210031  0.01
2006 Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, Michaud LB, Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 4107-15. PMID 16908934 DOI: 10.1200/JCO.2005.04.9551  1
2006 Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R, Sneige N, Ross JS, Vidaurre T, Gómez HL, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 4236-44. PMID 16896004 DOI: 10.1200/JCO.2006.05.6861  0.01
2006 Armstrong T, Cohen MZ, Hess KR, Manning R, Lee EL, Tamayo G, Baumgartner K, Min SJ, Yung A, Gilbert M. Complementary and alternative medicine use and quality of life in patients with primary brain tumors. Journal of Pain and Symptom Management. 32: 148-54. PMID 16877182 DOI: 10.1016/J.Jpainsymman.2006.02.015  1
2006 Colman H, Giannini C, Huang L, Gonzalez J, Hess K, Bruner J, Fuller G, Langford L, Pelloski C, Aaron J, Burger P, Aldape K. Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas. The American Journal of Surgical Pathology. 30: 657-64. PMID 16699322 DOI: 10.1097/01.Pas.0000202048.28203.25  1
2006 Ito H, Aoki H, Kühnel F, Kondo Y, Kubicka S, Wirth T, Iwado E, Iwamaru A, Fujiwara K, Hess KR, Lang FF, Sawaya R, Kondo S. Autophagic cell death of malignant glioma cells induced by a conditionally replicating adenovirus. Journal of the National Cancer Institute. 98: 625-36. PMID 16670388 DOI: 10.1093/Jnci/Djj161  1
2006 Groves MD, Puduvalli VK, Conrad CA, Gilbert MR, Yung WK, Jaeckle K, Liu V, Hess KR, Aldape KD, Levin VA. Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status. Journal of Neuro-Oncology. 80: 83-90. PMID 16639492 DOI: 10.1007/S11060-006-9160-Y  1
2006 Wang L, Wei Q, Wang LE, Aldape KD, Cao Y, Okcu MF, Hess KR, El-Zein R, Gilbert MR, Woo SY, Prabhu SS, Fuller GN, Bondy ML. Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 1627-32. PMID 16575014 DOI: 10.1200/Jco.2005.04.0402  1
2006 Anderson K, Hess KR, Kapoor M, Tirrell S, Courtemanche J, Wang B, Wu Y, Gong Y, Hortobagyi GN, Symmans WF, Pusztai L. Reproducibility of gene expression signature-based predictions in replicate experiments. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 1721-7. PMID 16551855 DOI: 10.1158/1078-0432.CCR-05-1539  0.01
2006 Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K, ... Hess K, et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro-Oncology. 8: 189-93. PMID 16533878 DOI: 10.1215/15228517-2005-010  1
2006 Li D, Frazier M, Evans DB, Hess KR, Crane CH, Jiao L, Abbruzzese JL. Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 1720-8. PMID 16520463 DOI: 10.1200/Jco.2005.04.4206  0.01
2006 Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL. Metastatic patterns in adenocarcinoma. Cancer. 106: 1624-33. PMID 16518827 DOI: 10.1002/cncr.21778  0.01
2006 Levin VA, Giglio P, Puduvalli VK, Jochec J, Groves MD, Yung WK, Hess K. Combination chemotherapy with 13-cis-retinoic acid and celecoxib in the treatment of glioblastoma multiforme. Journal of Neuro-Oncology. 78: 85-90. PMID 16391896 DOI: 10.1007/S11060-005-9062-4  1
2006 Xiong HQ, Wolff RA, Hess KR, Varadhachary GR, Blais JC, Abbruzzese JL. A phase II trial of oxaliplatin plus capecitabine (xelox) as second line therapy for patients with advanced pancreatic cancer Journal of Clinical Oncology. 24: 4119-4119. DOI: 10.1200/JCO.2006.24.18_SUPPL.4119  0.01
2006 Puduvalli VK, Giglio P, Groves MD, Hess KR, Gilbert M, Mahankali S, Hsu S, Colman H, Conrad C, Levin VA, Yung WKA. Phase II study of the combination of thalidomide and irinotecan in patients with recurrent anaplastic gliomas not on enzyme inducing anticonvulsants Journal of Clinical Oncology. 24: 1564-1564. DOI: 10.1200/Jco.2006.24.18_Suppl.1564  1
2006 Levin VA, Hess KR. Study design considerations for phase II trials of anaplastic gliomas and its impact on phase III survival studies Journal of Clinical Oncology. 24: 1501-1501. DOI: 10.1200/JCO.2006.24.18_SUPPL.1501  0.01
2006 Pusztai L, Hess KR, Anderson K, Valero V, Ibrahim NK, Mejia JA, Vidaurre T, Gomez HL, Hortobagyi GN, Symmans WF. Pharmacogenomic predictor of complete response to preoperative paclitaxel and 5-fluorouracil, doxorubicin, cyclophosphamide chemotherapy in breast cancer Journal of Clinical Oncology. 24: 10000-10000. DOI: 10.1200/JCO.2006.24.18_SUPPL.10000  0.01
2006 Lecocke M, Hess K. An Empirical Study of Univariate and Genetic Algorithm-Based Feature Selection in Binary Classification with Microarray Data Cancer Informatics. 2: 313-327. DOI: 10.1177/117693510600200016  0.01
2006 Hess K. A History of Rational Homotopy Theory History of Topology. 757-796. DOI: 10.1016/B978-044482375-5/50028-6  1
2005 Puduvalli VK, Giglio P, Groves MD, Hess KR, Jackson E, Mahankali S, Gilbert M, Levin VA, Conrad C, Hsu S, Yung WK. Phase II trial of thalidomide in combination with irinotecan in adults with recurrent glioblastoma multiforme. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 1524. PMID 27947138 DOI: 10.1200/Jco.2005.23.16_Suppl.1524  1
2005 Groves MD, Puduvalli V, Gilbert MR, Conrad CA, Hsu S, Colman H, Hess K, Levin VA, Yung WK. A phase II study of temozolomide plus pegylated interferon alfa-2b for recurrent anaplastic glioma and glioblastoma multiforme. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 1519. PMID 27947136 DOI: 10.1200/Jco.2005.23.16_Suppl.1519  1
2005 Xiong HQ, Hess KR, Kayaleh OR, Goodwin JW, Banerjee T, Sinclair SS, Fisch MJ, Wolff RA, Abbruzzese JL. A phase II trial of gemcitabine and celecoxib for metastatic pancreatic cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4174. PMID 27944631 DOI: 10.1200/jco.2005.23.16_suppl.4174  1
2005 Yao JC, Ng C, Hoff PM, Phan AT, Hess K, Chen H, Wang X, Abbruzzese JL, Ajani JA. Improved progression free survival (PFS), and rapid, sustained decrease in tumor perfusion among patients with advanced carcinoid treated with bevacizumab. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 4007. PMID 27944334 DOI: 10.1200/Jco.2005.23.16_Suppl.4007  1
2005 Symmans WF, Fiterman DJ, Anderson SK, Ayers M, Rouzier R, Dunmire V, Stec J, Valero V, Sneige N, Albarracin C, Wu Y, Ross JS, Wagner P, Theriault RL, Arun B, ... ... Hess KR, et al. A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. Endocrine-Related Cancer. 12: 1059-69. PMID 16322343 DOI: 10.1677/erc.1.01051  1
2005 Rouzier R, Pusztai L, Delaloge S, Gonzalez-Angulo AM, Andre F, Hess KR, Buzdar AU, Garbay JR, Spielmann M, Mathieu MC, Symmans WF, Wagner P, Atallah D, Valero V, Berry DA, et al. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 8331-9. PMID 16293864 DOI: 10.1200/JCO.2005.01.2898  0.01
2005 Zhou YH, Hess KR, Liu L, Linskey ME, Yung WK. Modeling prognosis for patients with malignant astrocytic gliomas: quantifying the expression of multiple genetic markers and clinical variables. Neuro-Oncology. 7: 485-94. PMID 16212813 DOI: 10.1215/S1152851704000730  1
2005 Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, et al. Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy Clinical Cancer Research. 11: 5678-5685. PMID 16115903 DOI: 10.1158/1078-0432.Ccr-04-2421  1
2005 McDonald JM, See SJ, Tremont IW, Colman H, Gilbert MR, Groves M, Burger PC, Louis DN, Giannini C, Fuller G, Passe S, Blair H, Jenkins RB, Yang H, Ledoux A, ... ... Hess K, et al. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer. 104: 1468-77. PMID 16088966 DOI: 10.1002/Cncr.21338  1
2005 Stec J, Wang J, Coombes K, Ayers M, Hoersch S, Gold DL, Ross JS, Hess KR, Tirrell S, Linette G, Hortobagyi GN, Fraser Symmans W, Pusztai L. Comparison of the predictive accuracy of DNA array-based multigene classifiers across cDNA arrays and Affymetrix GeneChips. The Journal of Molecular Diagnostics : Jmd. 7: 357-67. PMID 16049308 DOI: 10.1016/s1525-1578(10)60565-x  1
2005 Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, De Angelis L, Raizer J, Hess K, Aldape K, Lamborn KR, Kuhn J, Dancey J, et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Investigational New Drugs. 23: 357-61. PMID 16012795 DOI: 10.1007/S10637-005-1444-0  1
2005 Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J, Ayers M, Ross JS, Zhang P, Buchholz TA, Kuerer H, Green M, Arun B, Hortobagyi GN, Symmans WF, et al. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 102: 8315-20. PMID 15914550 DOI: 10.1073/pnas.0408974102  1
2005 Sclabas GM, Uwagawa T, Schmidt C, Hess KR, Evans DB, Abbruzzese JL, Chiao PJ. Nuclear factor kappa B activation is a potential target for preventing pancreatic carcinoma by aspirin. Cancer. 103: 2485-90. PMID 15861417 DOI: 10.1002/Cncr.21075  1
2005 Yao JC, Tseng JF, Worah S, Hess KR, Mansfield PF, Crane CH, Schnirer II, Reddy S, Chiang SS, Najam A, Yu C, Giacco GG, Xie K, Wu TT, Feig BW, et al. Clinicopathologic behavior of gastric adenocarcinoma in Hispanic patients: analysis of a single institution's experience over 15 years. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 3094-103. PMID 15860869 DOI: 10.1200/JCO.2005.08.987  1
2005 Zhou YH, Wu X, Tan F, Shi YX, Glass T, Liu TJ, Wathen K, Hess KR, Gumin J, Lang F, Yung WK. PAX6 suppresses growth of human glioblastoma cells. Journal of Neuro-Oncology. 71: 223-9. PMID 15735909 DOI: 10.1007/s11060-004-1720-4  1
2005 Heimberger AB, Wang E, McGary EC, Hess KR, Henry VK, Shono T, Cohen Z, Gumin J, Sawaya R, Conrad CA, Lang FF. Mechanisms of action of rapamycin in gliomas. Neuro-Oncology. 7: 1-11. PMID 15701277 DOI: 10.1215/S1152851704000420  1
2005 Pusztai L, Hess KR. Clinical trial design for microarray predictive marker discovery and assessment. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 15: 1731-7. PMID 15550577 DOI: 10.1093/ANNONC/MDH466  0.01
2005 Rashid A, Hess KR, Lenzi R, Raber MN, Abbruzzese JL, Varadhachary GR. Overexpression and prevalence of molecular markers in patients with cancer of unknown primary (CUP) Journal of Clinical Oncology. 23: 9683-9683. DOI: 10.1200/JCO.2005.23.16_SUPPL.9683  0.01
2005 Symmans WF, Sotiriou C, Anderson KS, Valero V, Booser DJ, Hess KR, Ross JS, Piccart M, Hortobagyi GN, Pusztai L. Use of DNA microarrays to determine estrogen and HER-2 receptor status in breast cancer Journal of Clinical Oncology. 23: 546-546. DOI: 10.1200/JCO.2005.23.16_SUPPL.546  0.01
2005 Hess K, Philipp W. Bell's theorem: Critique of proofs with and without inequalities Aip Conference Proceedings. 750: 150-157. DOI: 10.1063/1.1874568  1
2005 Hess K. Lembegleitung im Mathematik-Unterricht: Ansprüche, Funktionen, Bedingungen und Realitäten Journal Fur Mathematik-Didaktik. 26: 224-248. DOI: 10.1007/BF03339024  1
2004 Pusztai L, Wang J, Coombes K, Hoersch S, Ayers M, Ross J, Hess K, Hortobagyi G, Symmans W, Stec J. Cross platform comparison of multigene predictors of response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer generated by cDNA arrays and Affymetrix GeneChips. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 503. PMID 28016109 DOI: 10.1200/Jco.2004.22.14_Suppl.503  1
2004 Puduvalli VK, Yung WK, Hess KR, Kuhn JG, Groves MD, Levin VA, Zwiebel J, Chang SM, Cloughesy TF, Junck L, Wen P, Lieberman F, Conrad CA, Gilbert MR, Meyers CA, et al. Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 4282-9. PMID 15514370 DOI: 10.1200/Jco.2004.09.096  1
2004 Hess KR, Broglio KR, Bondy ML. Adult glioma incidence trends in the United States, 1977-2000 Cancer. 101: 2293-2299. PMID 15476282 DOI: 10.1002/Cncr.20621  1
2004 Xiong HQ, Herbst R, Faria SdC, Scholz C, Davis D, Jackson EF, Madden T, McConkey DJ, Hicks ME, Hess KR, Charnsangavej C, Abbruzzese JL. A phase I surrogate endpoint study of SU6668 in patients with solid tumors Investigational New Drugs. 22: 459-466. PMID 15292716 DOI: 10.1023/B:Drug.0000036688.96453.8D  1
2004 Chang SM, Kuhn J, Wen P, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, Cloughesy T, De Angelis L, Razier J, Hess K, Dancey J, Prados MD. Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Investigational New Drugs. 22: 427-35. PMID 15292713 DOI: 10.1023/B:Drug.0000036685.72140.03  1
Show low-probability matches.